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Summary 
Background:  
Cardiovascular diseases (CVD) constitute one of the most significant causes 
of morbidity and are among the three most frequent causes of death in in-
dustrial countries. They comprise coronary heart disease (CHD), cere-
brovascular disease and peripheral artery disease (PAD).  
While death rates from CVD have been decreasing in many European coun-
tries including Austria, CVD still account for the largest proportions of hos-
pital stays. The high burden of disease also has economic implications. 
Health care costs of 1.6 billion Euros, 6 % of the health care budget, were es-
timated for 2006 for Austria.  
Several risk factors have been identified as causes of CVD, one of them be-
ing an elevated ‘Low Densitiy Lipoprotein-level’ (LDL-level). Among a 
number of measures to reduce serum cholesterol, pharmacological treatment 
with ‘HMG-CoA Reductase Inhibitors’ (statins) has become increasingly 
dominant since the beginning of the 1990s.  
In clinical studies and meta-analyses, statins have shown significant risk re-
ductions with respect to several clinical endpoints such as all-cause mortal-
ity, CHD mortality and CHD morbidity and exhibited a high level of safety. 
Between 1996 and 2006 the number of prescriptions for statins rose from 
around half a million to 3.5 million in Austria, corresponding to 0.5 % and 
3.1 % of all prescriptions respectively. While the costs per prescription de-
creased from around 40 Euros to 20 Euros due to the introduction of gener-
ics, overall expenditure rose sharply from 15 million Euros in 1996 to 94 
million Euros in 2003 and then decreased to 76 million Euros in 2006.  
Research question:   
b How many persons were taking statins between 1996 and 2006 in Aus-
tria and what are the expected population health gains from statin 
treatment in the secondary prevention of CVD for patients with CHD 
compared to standard advice without statins? 
b What is the cost-utility of statin therapy compared to standard advice 
without statins in the secondary prevention of CVD for patients with 
CHD from a public payer perspective? 
Method:  
First, model outcomes from a validated and adapted Markov model from the 
UK that compared statin takers with non-statin takers (based on clinical 
trial evidence) were related to the actual number of Austrian statin patients 
from 1996 to 2006. Population effects with regard to non lethal and lethal 
types of CVD and revascularisation interventions were calculated.  
Second, model outcomes were used to analyse 10-year and life-time cost-
utility ratios from a public payer perspective, discounted at 5 %.  
One-way sensitivity analyses were conducted to address uncertainty. 
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Results: 
Population health gains: 
In the base case, it was demonstrated that roughly 36,200 patients started 
taking statins in 1996. The new cohorts per year were constantly rising and 
in 2006, about 108,000 new patients were estimated taking the medication. 
Overall, it was estimated that roughly 600,000 patients were taking statins in 
the 11-year observation period.  
Of these, around 856 fewer cases of unstable angina, 26,600 fewer MIs and 
1,100 fewer strokes occurred, while roughly 6,100 more cases of stable angina 
were estimated when compared to not taking statins. In other words, 21 per-
sons had to be treated with statins in order to avoid (or postpone) one pa-
tient going into a CVD health state. 
Furthermore, it was estimated that in the 600,000 statin takers, 10,300 fatal 
CVD events (10,200 CHD deaths and 100 cerebrovascular deaths) were 
avoided or postponed. Put differently, 59 persons had to take statins between 
1996 and 2006 in order to avoid or delay one fatal CVD event.  
Finally, the 600,000 statin patients can be weighed against around 7,000 re-
vascularisation interventions avoided meaning 86 patients were treated to 
avoid one revascularisation intervention. 
It was demonstrated in the model that in spite of statins about 42,000 cases 
of unstable angina, MI or stroke occurred and 25,400 fatal events (24,000 
CHD deaths and 1,400 cerebrovascular deaths) happened. A total of 231,000 
revascularisation interventions were carried out in spite of statin treatment.  
Costs: 
Total net costs were estimated at 33 million Euros in 1996 and 673 million 
Euros in 2007. From the latter, 76 million Euros were related to statin 
treatment only, while further costs to treat CVD were estimated at about 600 
million Euros. Potential cost-containment rose from 8 million Euros to 105 
million Euros in 2007. 
Cost-utility: 
Depending on the age-group, discounted incremental costs are between 
2,400 and 7,800 Euros for males and between 2,500 and 8,000 Euros for fe-
males. Discounted QALYs per person are between 0.21 and 0.37 in males 
and between 0.20 and 4.19 in females. Incremental cost-utility ratios range 
from 11,400 to 23,200 Euros per QALY in males and from 12,500 to 23,000 
Euros per QALY in females. The ratios decrease with age. In a ten-year time 
frame, cost-utility ratios rise to more than 60,000 Euros per QALY in 
younger age groups. 
Sensitivity analysis: 
Cost-utility results are sensitive to statin costs and discount rates (ratios are 
lower when lower costs and discount rates are assumed) and to compliance 
in the younger age groups (higher ratios with lower compliance) 
Cohort sizes and population health gains are sensitive to varying gender and 
age distributions in statin takers. Choosing a distribution that is close to the 
socio-demographic characteristics in patients hospitalised for MI, led to in-
creasing cohort sizes (750,000 instead of 600,000 patients in 11 years) and to 
more health gains, especially with regard to MI and fatal CHD. 
˜ 600,000 statin takers 
between 1996 and 2006 
NNT to avoid 1 person 
going into CVD health 
state: 21 
NNT to avoid 1 fatal 
event: 59 
NNT to avoid 1 
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females: 12,500 to 
23,000 €/QALY 
results sensitive to 
statin costs, discount 
rates, compliance… 
…and to gender/age 
distribution of statin 
takers 
Summary 
LBI-HTA | 2008 9 
Discussion: 
In roughly 600,000 patients who took statins between 1996 and 2007 about 
26,600 cases of MI and roughly 10,200 cases of fatal CHDs (mostly MIs) 
seem to have been avoided or postponed. The effect on (fatal) stroke was low. 
Moreover, about 7,000 fewer revascularisation interventions have been esti-
mated compared to not taking statins. However, the model demonstrated 
that about 68,000 CVD cases or fatal events and 230,000 revascularisation 
interventions still occurred in spite of statin treatment.  
Overall, a considerable number of persons needed to be treated to achieve 
health gains in one: 21 patients needed to be treated in order to 
avoid/postpone one patient going into a CVD health state. Furthermore, 59 
patients needed to be treated to avoid/postpone one fatal event and 86 pa-
tients needed to take statins to avoid one revascularisation intervention. 
These results are consistent with the literature.  
ICURs are mostly below 30,000 Euros per QALY gained but rise above 
60,000 Euros per QALY gained in younger age groups when analysed from a 
ten-year perspective. Again, results are consistent with the literature; how-
ever, in the absence of a willingness-to-pay threshold in Austria, interpreta-
tion of the cost-utility results is limited. 
Further limitations exist for the following reasons: First, many parameters 
in the model are from the UK because they were not available for Austria. 
Second, Austrian cohort sizes and estimated population health gains are 
subject to uncertainty. Third, statin prescription data used may include 
primary prevention cases. Furthermore, the administrative data used for 
cost-calculation are sub-optimal and cost-calculation did not take into ac-
count societal effects from therapy such as the impact on informal care. 
Moreover, the model outputs are based on the results from clinical statin tri-
als and transfer to routine practice may be limited.  
Conclusion: 
Results suggest that prescribing statins to about 600,000 to 750,000 patients 
in the period between 1996 and 2006 should have resulted in observable 
population health gains (especially with respect to MI and CHD death), 
compared to the alternative of not taking the medication.  
Nevertheless, the 45,000 avoided or postponed CVD cases, fatal events or re-
vascularisation interventions need to be balanced against 300,000 CVD 
cases, fatal events or interventions that still occurred.  
Both, the size of the statin cohort and the health gains are subject to some 
uncertainty and therefore should be interpreted as rough estimates rather 
than precise figures.  
Cost-utility ratios were mostly below 30,000 Euros per QALY gained which 
has been rated as favourable in other countries. Whether the expected health 
gains are sufficient after weighing benefits and costs is a matter of political 
and public debate. 
Further research is required which should address primary prevention and 
sub-group analysis. Moreover, verification is needed on whether expected 
health gains are observable in Austrian cardiovascular disease epidemiology. 
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1 Introduction  
Cardiovascular diseases (CVD) are among the most prevalent diseases in in-
dustrial countries. They result in high morbidity and mortality rates. A high 
blood cholesterol level is regarded as one of several significant risk factors of 
CVD. Several primary and secondary prevention strategies have been devel-
oped which focus on reducing serum cholesterol. They are dominated by 
pharmacological interventions. The most widely used products are statins 
(cholesterol lowering drugs). They were introduced in the beginnings of the 
1990s and have since dominated the market of cholesterol lowering drugs.   
The use of statins has not only been proven to be efficacious in clinical stud-
ies but they have also been described as being cost-effective in economic 
evaluations. The reason for the latter is primarily that clinical studies 
showed reductions in hospital interventions. Thus some of the additional 
costs of statin therapy can apparently be offset by savings in hospital costs. 
Since their introduction use of and expenditure for statins have risen dra-
matically. Already in 2000, expenditure for statins in EU-15 countries and 
Norway was equal to 4 billion Euros and rose to over 20 billion Euros be-
tween 2000 and 2004 [1]. 
From a Health Technology Assessment (HTA) perspective the constant in-
crease in the use of statins should be viewed with a critical eye and the bene-
fits need to be assessed. Even though efficacy has been proven in clinical 
studies, several questions remain unanswered. First of all, clinical studies 
only cover a selected study population and show efficacy under ideal condi-
tions. However, they do not show the effectiveness of therapy under ‘real-
life’ conditions and they say little about the overall population health impact 
of statins. Secondly, available economic evaluations are primarily based on 
effect sizes of statins from clinical studies and may over- or underestimate 
the cost-effectiveness results in real life [2]. Finally, country specific factors 
may make it difficult to transfer results of studies to one’s own country and 
may thus require a separate analysis. 
For addressing these issues for Austria, a mathematical model will be used 
in order to predict costs, outcomes and the cost-effectiveness of statin ther-
apy for the secondary prevention of CVD within the context of an Austrian 
health care system. The model outputs will be used to estimate population 
health gains and costs for the period since statins have been introduced into 
the Austrian market up to 2006.  
The report is divided into several chapters. Chapter 2 specifies the research 
question. Chapter 3 describes the public health background of CVD, the 
medical background of statins and the economic background in terms of in-
ternational economic evaluation studies on statins. Furthermore, the devel-
opment of statin use in Austria will be described. Chapter 4 introduces the 
model and its methodological characteristics.  In chapter 5, the results will 
be presented. A discussion of the results and of the limitation of the method 
is provided in chapter 6. The report closes with concluding remarks for deci-
sion makers and researchers.  
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2 Research Question 
The study aims at  
1. Evaluating expected health gains from statins compared to standard ad-
vice without statins in the secondary prevention of CVD in Austria based 
on the actual number of patients with coronary heart disease (CHD) who 
have been treated with statins. The calculations will additionally address 
the number of (reduced) hospital interventions linked with statin pre-
scriptions. 
2. Evaluating the 10-year and life-time cost-utility of statin therapy com-
pared to standard advice without statins in the secondary prevention of 
CVD for patients with CHD in Austria from the perspective of the public 
payers.  
The specific research questions are: 
1. What are the annual sizes of ‘statin patient cohorts’ in Austria? 
2. What is the 11-year effectiveness (1997 to 2007) in terms of population 
health of statins compared to standard advice only for the following clini-
cal parameters? 
a. Non-lethal cardiovascular events (myocardial infarction, stable and 
unstable angina, stroke) 
b. Hospital interventions (percutaneous coronary intervention, coro-
nary artery bypass grafting) 
c. CHD/CVD-specific mortality 
3. What is the life-time effectiveness of statins compared to standard advice 
only in terms of quality-adjusted life years gained (QALY)? 
4. What are the 10-year and life-time 
a. Costs for the health care system (direct costs only) and the 
b. Incremental cost-utility ratios  
of statins compared to standard advice only 
The analysis is restricted to secondary prevention of CVD for patients with 
clinically manifest CHD. In terms of definition, CHD is defined as clini-
cally manifest MI, stable or unstable angina (including fatal events). CVD is 
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3 Background 
3.1 Public Health Background 
Diseases of the heart and circulatory system (cardiovascular diseases or 
CVD) are among the three most frequent causes of death in industrial coun-
tries and constitute one of the most significant causes of morbidity [3]. Ac-
cording to the ‘European Cardiovascular Statistics’, every year in Europe 4.3 
million people die from CVD [4]. This accounts for almost half of all deaths 
in Europe. 
CVD comprises several types of disease including coronary heart disease 
(CHD), cerebrovascular disease, and peripheral-artery disease (PAD). CHD 
encompasses myocardial infarction (MI), stable and unstable angina (SA 
and USA) as well as other chronic heart diseases. Concerning the burden of 
disease, in Europe just under half of all deaths from CVD are from CHD. 
Additionally, CHD is by itself the single most common cause of death in 
Europe, accounting for 1.92 million deaths each year [4]. This demonstrates 
the significance of CHD among CVD.  
Similar to other countries, cardio-vascular diseases are also a significant fac-
tor for all-cause-mortality in Austria. In 2006, 43.7 % (32,489 persons) of 
deaths were caused by cardio-vascular diseases [5]. In terms of frequency, 
CHD is also the most prevalent type of CVD in Austria. In 2006, 20.1 % 
(14,960) of all deaths were related to CHD. Eight percent of all deaths were 
caused by MI which equals 5,969 persons. With respect to gender, the death 
rate due to MI is twice as high for males as for females. However, with re-
spect to all CVD deaths, women more frequently die from CVD than men 
(48.9 % versus 37.9 %) [5]. 
Over the past 30 years death rates from CVD have been declining in most 
northern and western European countries. According to several studies, the 
highest proportion of decline in CHD (around two thirds) is attributable to 
reduced incidence rates while the remaining third is due to improved treat-
ment [6, 7]. 
Like in most northern and western European countries, death rates from 
CVD have also been decreasing in Austria. Over the last ten years – between 
1996 and 2006 – mortality due to CVD fell by 40.9 %. Standardised for age, 
mortality due to MI fell by 44.5 %. The trend has been increasingly evident 
since the beginnings of the 1990s [5].  
The significance of CVD is also reflected in hospital statistics. In all Euro-
pean countries, rates for revascularisation have increased since the 1990ies. 
In some countries, in Hungary for example the revascularisation rate has in-
creased up to 20-fold [8]. However, hospital discharge rates as well as inter-
vention rates vary considerably from country to country.  
In Austria, CVD-diagnoses accounted for 12.2 % of all hospital diagnoses in 
2005. This was the largest proportion compared to other diagnostic groups. 
Although the mean length of stay for persons with a CVD diagnosis has con-
tinuously decreased for CVD (from 12 days in 2003 to 7.8 days in 2005), it is 
still higher than the average length of stay of 5.9 days. In 2005, around 3,800 
men and 3,600 women per 100,000 inhabitants were treated for a type of 
CVD [5].  
CVD: 4.3 million deaths 
per year in Europe 
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Several risk factors have been identified as causes for CVD. One of them is 
hyperlipidaemia, more precisely a high ‘Low-Density-Lipoprotein-Level’ 
(LDL). Causality between an increased level of serum cholesterol and in-
creased risk for CVD has been shown in several studies, however, it has also 
been noted that by itself, serum cholesterol is a limited predictor for cardio-
vascular events1[9]. Hyperlipidaemia is therefore only one of several risk 
factors which need to be considered in prevention programmes. In other 
words reducing cholesterol is only one out of several measures to reduce risk 
of morbidity and mortality. 
Several measures have been developed to reduce serum-cholesterol. Some of 
them address the life-style (e. g. diet), while others are pharmacological in-
terventions. One of the most important pharmacological interventions is the 
‘Hydroxymethylglutaryl-CoA Reductase Inhibitors’ (HMG-CoA Reductase-
Inhibitors), also called statins which were launched in the beginnings of the 
1990ies. Since then the number of prescriptions and expenditure for statins 
have risen considerably. An OECD report from 2003 showed that from all of 
the pharmaceuticals used for the prevention and treatment of CVDs (e.g. 
ACE inhibitors), statins showed the highest rates of increase in costs and 
utilisation [10].   
3.2 Medical Background 
Statins inhibit the HMG-CoA which is an enzyme that is required for the 
synthesis of cholesterol. This results in reduced cholesterol production in 
the liver and subsequently LDL receptors are increasingly formed on the 
liver-cell surface. The circulating LDL adheres to these receptors. In addi-
tion, statins have shown so-called ‘pleiotropic’ effects which are not neces-
sarily linked with cholesterol reduction. For example they have shown im-
proved vessel function in vitro [i.e. 11, 12]. Whether these effects will also be 
verifiable in vivo remains to be seen. Statins are either produced via fungal 
fermentation or synthetically [13].  
Several studies have shown that statins are efficacious in terms of effects on 
surrogate endpoints (e.g. reduction of cholesterol level) and clinical end-
points (reduction of morbidity and mortality). In a meta-analysis from 2005, 
31 randomised controlled trials were analysed, which investigated the effect 
of statins in patients with pre-existing and manifest CVD [14]. The meta-
analysis showed a significant risk reduction of all-cause-mortality, of cardio-
vascular mortality and of fatal MI. However, the analysis did not show a sig-
nificant risk reduction in fatal stroke. Yet, the study reported a significant 
reduction of non-fatal endpoints such as non-fatal stroke, non-fatal MI, un-
stable Angina and coronary revascularisation.  
In terms of absolute risk reduction, the biggest effect size was shown for the 
combined endpoint of CHD mortality and morbidity. Depending on the 
study, average absolute risk reduction was between 3 % (CARE study) and 
8.57 % (4S-Study) corresponding to a number-needed to treat of 34 (22.8-
95.5) and 12 (9-16.4) [14].  
                                                             
1 For example, according to the British Regional Heart Survey only 42 % of men who 
developed CHD over a 15-year period had elevated cholesterol-levels above 6,5 
mmol/l.  
hyperlipidaemia (LDL) 
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Statins have exhibitied a high level of safety. Nevertheless, some side-effects 
have been reported. The most frequently mentioned side-effect (1 out of 
1,000 users) is myopathia which is manifested in muscle pain and amyas-
thenia. If undetected, this can lead to rhabdomyolysis and acute renal-
failure. However, in clinical studies such serious side-effects have been 
rarely reported. In rare cases, liver-dysfunction, renal-failure, hypothyreosis 
and infectious diseases can occur [13]. Occasionally, patients suffered from 
headache, dizziness, rash, diarrhoea, abdominal pain or constipation [14]. 
The side-effects are usually dependent on drug doses and are reversible if 
the drug dose is reduced in sufficient time. To prevent liver and muscle 
damage diagnostic tests for liver- and muscle enzymes are recommended 
[13].  
3.3 Economic Background 
CVDs are linked with a high burden of disease which also has economic im-
plications. According to the European cardiovascular disease statistics [4], 
total cost of CVD in Europe has been estimated to be around 192 billion Eu-
ros in 2006. This represents a cost per capita of 391 Euros. Around two 
thirds of the costs occur within the health care sector where they account for 
10 % of the total health care expenditure across the EU. The remainder are 
incurred by productivity losses and costs of informal care.  
CHD is estimated to cost the EU economy around 49 billion Euros per year 
which accounts for just over one quarter of the overall CVD costs. From the 
total CHD costs, around half are due to direct health care costs, a third to 
productivity losses and 15 % are due to informal care for people with CHD 
[4].  
For Austria, the same study reports CVD costs for the health care sector of 
1.6 billion Euros or 6 % of the total health care budget for the year 2006. In-
patient care accounted for the highest proportion of 54 % (0.8 billion Euros) 
[4]. 
Consequently, prevention and treatment are not only seen in terms of clini-
cal benefits but also with respect to economic benefits. In that context, sev-
eral studies have presented economic evaluations of statins. Usually, evalua-
tors conducted cost-effectiveness or cost-utility analyses. A systematic review 
of existing economic evaluations from 2005 reports thirty-five economic 
evaluations which address secondary prevention with statins [2]. 
In summary the studies have shown that outcome from life-long statin 
treatment ranges on average from 0.11 to 0.44 life years gained (LYG) per 
person (which equals 1.3 to 6 life months gained (LMG) per person) or from 
0.13 to 0.49 quality adjusted life years (QALY) per person. Additional costs 
as well as incremental cost-effectiveness or cost-utility ratios mostly lie be-
low 10,000 Euros per LYG or QALY. This has been estimated to be cost-
effective when compared to other accepted medical interventions or to (in-
formally) existing willingness-to-pay thresholds [e.g. 14, 15, 16-21].      
Based on clinical studies, economic evaluations have shown reductions of 
hospital costs resulting in cost-offset of statin costs between 25 % and 85 %, 
however, additional costs for medication were not fully compensated by sav-
ings. The most favourable cost-effectiveness results are to be expected in 
good safety profile 
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countries with high rates of hospital admissions and long lengths of stay be-
cause the potential for cost-offset is higher in those countries. Yet, authors 
have also reported that the increasing use of statins in an unselected study 
population may also lead to unfavourable cost-effectiveness results [2].  
3.4 Current Service Provision:  
Use of Statins in Austria 
3.4.1 Legal Regulations and Guidelines  
In Austria, public reimbursement of licensed pharmaceuticals is regulated 
via a so-called positive list (Erstattungskodex/EKO). Statins have been in-
cluded in the positive list of the social health insurance since the mid 1990s. 
The first regulation stipulated that statins are reimbursed when used for 
secondary prevention in patients with diagnosed CHD and hypercholes-
terinaemia.  
In terms of definition, diagnosed CHD means [22] 
b Clinically verified angina (electrocardiogram, ergometry or scintigra-
phy, probably coronary angiography) or 
b Patients after myocardial infarction (MI) or 
b Patients after percutaneous transluminal coronary angiography 
(PTCA) or 
b Patients after coronary artery bypass grafting (CABG) 
b Hypercholesterinaemia is defined as  
b LDL cholesterol > 100 mg/dl 
b Quotient total cholesterol/HDL > 3 
 
This regulation was changed in 2004. Since then statins are reimbursed for 
patients with clinically manifest atherosclerosis and/or diabetes with high 
risk for cardio-vascular events.  
Clinically manifest atherosclerosis is defined as 
b Coronary heart disease (CHD) 
b Cerebrovascular disease  
b Peripheral artery disease (PAD) 
 
Concerning guidelines for treatment in secondary prevention, pharmacol-
ogical treatment is suggested in addition to life-style interventions (weight 
reduction, dietary advice, smoking prohibition, exercise). Pharmacological 
treatment is to be started at the lowest dose.  
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3.4.2 Volumes and Expenditure from a Historical 
Perspective 
The estimation of volumes and expenditure is based on data from the Fed-
eration of the Austrian Social Insurance Institutions. This data provides the 
number of prescriptions and related expenditure for all types of statins be-
tween 1996 and 2006.  
Table 3.4-1 gives an overview of all statins (including generics) which have 
been covered publicly between 1996 and 2006.  
With respect to statin types, six types have been included in the positive list 
between 1996 and 2006. These are 
b Atorvastatin (Sortis ®) 
b Fluvastatin (Lescol ®) 
b Lovastatin (Mevacor ® + Generics) 
b Pravastatin (Pravachol ®, Selipran ® + Generics) 
b Rosuvastatin (Crestor ®) 
b Simvastatin (Zocord ® + Generics) 
 
database:         
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Table 3.4-1: Licensed statins in Austrian positive list between 1996 and 2006 
Source: Federation of Austrian Social Insurance Institutions 
 
Active Ingredient Trade name Manufacturer 
Atorvastatin Sortis® Filmtabletten (10, 20, 40, 80 mg) Pfizer 
Fluvastatin Lescol® 40 mg Kapseln 
Lescol MR® 80 mg Filmtabletten 
Novartis 
Novartis 
Lovastatin Mevacor® 20 mg Tabletten 
Mevacor forte® 40 mg Tabletten 
Generikum ‘Alternova’20 mg Tabletten 
Generikum ‘Hexal’ 20 mg Tabletten 
Gnerikum ‘Stada’ 20 mg Tabletten 
Merck Sharp & Dohme 




Pravastatin Pravachol® Tabletten (20, 40 mg) 
Selipran®  Tabletten (10, 20 mg) 
Generikum Sanaprav® Tabletten (20, 40  mg)  
Generikum Panchol® Tabletten (20, 40 mg) 
Generikum ‘1A Pharma’ Tabletten (20, 30, 40 mg) 
Generikum ‘Alternava’ Filmtabletten (20, 40 mg) 
Generikum ‘Genericon’ Filmtabletten (20, 40 mg) 
Generikum ‘Hexal’ Tabletten (20, 30, 40 mg) 
Generikum ‘Interpharm’ Tabletten  (20, 40 mg) 
Generikum ‘Ranbaxy’ Tabletten (20, 40 mg) 
Generikum ‘ratiopharm’ Tabletten (20, 40 mg) 
Generikum ‘Sandoz’ Tabletten (20, 40 mg) 














Rosuvastatin Crestor® Filmtabletten (5, 10, 20, 40 mg) Astra Zeneca 
Simvastatin Zocord® Filmtabletten (20, 40, 80 mg) 
Generikum Nyzoc® Filmtabletten (20, 40, mg) 
Generikum Gerosim® Filmtabletten (20, 40 mg) 
Generikum Simvastad® Filmtabletten (20, 40 mg) 
Generikum ‘1A Pharma’ Filmtabletten (20, 40 mg) 
Generikum ‚Alternova’ Filmtabletten (20, 40 mg) 
Generikum ‚Genericon’ Filmtabletten (20, 40 mg) 
Generikum ‚Hexal’ Filmtabletten (10, 20, 30, 40 mg) 
Generikum ‚Interpharm’ Filmtabletten (20, 40 mg) 
Generikum ‚Merck’ Filmtabletten (20, 40 mg) 
Generikum ‚Ranbaxy’ Filmtabletten (20, 40 mg) 
Generikum ‚ratiopharm’ Filmtabletten (20, 40 mg) 
Generikum ‚Sandoz’ Filmtabletten (20, 40 mg) 
Generikum Simvatin® Filmtabletten (20, 40 mg) 
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Statins have been available in different doses since 1996. Table 3.4-2 gives 
an overview of available doses per type of statin.  
Table 3.4-2: Available doses per type of statin 
Dose/Type 
of Statin 
5 mg 10  mg 20 mg 30 mg 40 mg 80 mg 
Atorvastatin  X X  X X 
Fluvastatin     X X 
Lovastatin   X  X  
Pravastatin  X X X X  
Simvastatin  X X X X X 
Rosuvastatin X X X  X  
 
The number of prescriptions varies considerably between different doses 
available. As shown in Table 3.4-3 for the year 2006, some doses hardly ever 
have been prescribed (e.g. rosuvastatin 5 mg) while others have been pre-
scribed more frequently (e.g. simvastatin or pravastatin 20 mg and 40 mg, 
fluvastatin 80 mg). 
Table 3.4-3: Number of statins prescribed in 2006 per doses and type of statin 
 Number of prescriptions 
Dose/Type 
of Statin 
5 mg 10  mg 20 mg 30 mg 40 mg 80 mg 
Atorvastatin 0 333,771 84,748 0 26,762 9,343 
Fluvastatin 0 0 0 0 171,118 337,254 
Lovastatin 0 0 21,566 0 64 0 
Pravastatin 0 46 259,112 3,038 123,650 0 
Simvastatin 0 172 1,131,848 25,914 769,782 311 
Rosuvastatin 17 54,896 12,291 0 2,710 0 
 
Figure 3.4-1 shows the numbers of total prescriptions for each type of statin 
between 1996 and 2006. The number of prescriptions has risen from 432,170 
in 1996 to 3,468,303 in 2006. In terms of statin type simvastatin accounts for 
the greatest proportion of statins prescribed (40%), followed by atorvastatin 
(28.5 %). Pravastatin and fluvastatin account for 16.7 and 11.3 % respec-
tively whereas lovastatin (2.9 %) and rosuvastatin (0.5 %) play a marginal 
role with respect to volume.  
Concerning the overall number of prescriptions for pharmaceuticals that 
rose from 93.2 millions in 1996 to 107.7 millions in 2006 in Austria [23, 24], 
statins accounted for 0.5 % in 1996. The proportion constantly increased up 
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Figure 3.4-1: Statin prescriptions 1996 to 2006 by type of statin 
As shown in Figure 3.4-2, expenditure for statins has also risen considerably 
since the mid-1990s. In 1996 the social insurance institutions paid around 17 
million Euros for statins. Expenditure peaked in 2003 where 94 million Eu-
ros were spent on statins.  In 2006 expenditure for statins decreased to 
around 76 million Euros. The decrease was due to the introduction of gener-
ics. Total expenditure between 1996 and 2006 were 705,228,505 Euros. 
Again, simvastatin and atorvastatin account for the biggest proportion of ex-
penditure, followed by pravastatin and fluvastatin. The costs per prescrip-
tion were 39.40 Euros in 1996 and decreased to 22.50 Euros in 2006 (see Fig-
ure 3.4-3).  
In terms of overall expenditure for pharmaceuticals in Austria that in-
creased from 1.4 billion in 1996 to 2.6 billion in 2006 [23, 24], the proportion 
paid for statins rose from 1.2 % in 1996 to 4.1 % in 2002. Since then, the 
share paid for statins has slightly decreased. In 2006 statins accounted for 
2.9 % of total expenditure for pharmaceuticals.  
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Figure 3.4-3: Cost per prescription 1996 to 2006 
According to the defined daily doses for each type of statin, the total number 
of prescribed daily doses of statins can be calculated. Figure 3.4-4 shows that 
the total number of prescribed daily doses rose more than tenfold from 
around 13 million in 1996 to 170.8 million in 2006. 
Figure 3.4-4: Total daily doses according to defined daily doses (DDD) from 
1996 to 2006 
According to Gouya et al. (2007) [25], data from the Austrian province ‘Bur-
genland’ showed that from all 207 patients discharged after an MI in 2003, 
68% were prescribed a lipid lowering agent. The frequency of lipid lowering 
drug prescription was significantly lower in women than in men. Similarly, 
Winkelmayer et al. [26] found from data covering three quarters of the in-
sured population in Austria that 67 % of patients who were discharged after 
an MI were prescribed a lipid lowering agent within 120 days. The oldest pa-
tients (>90 years) were less likely to receive statins, however, gender did not 
have a significant influence on prescriptions in that study.  
171 million prescribed 
daily doses in 2006 
lipid lowering drugs for 
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patients in Austria  
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4 Method 
4.1 Overview 
For the study a Markov-model which has been developed and validated at 
the University of Sheffield/School of Health and Related Research 
(ScHARR) was adapted for the context of the Austrian health care system 
and for the specific research questions to be addressed. This model was cho-
sen for several reasons 
b A Markov-model is appropriate for diseases with recurring events, for 
diseases involving risks that continue or increase over time and where 
the probability of an event occurring changes depending on the time 
since a previous event. This fits well with the characteristics of CVD. 
b The ScHARR model addresses a similar research question which 
should allow for adaptation, thus, avoiding duplication and redun-
dancies. 
b Effectiveness data in the ScHARR model are based on a meta-analysis 
and, thus, synthesise the available evidence. 
b The model generally fulfils the standards of modelling for economic 
evaluations. 
 
The model parameters are based on the following data sources: 
b Due to absence of valid Austrian data, initial distribution into differ-
ent health states and demographic characteristics of the cohort were 
adapted from the ScHARR model which is based on British registry 
data. 
b Progression between health states:  
o Transitional probabilities for MI, angina and stroke health 
states were used from the ScHARR model. They were derived 
from UK registry data for MI and stroke health states and 
from secondary literature for angina health states.  
o Progression to the health state ‘mortality other cause’ are 
based on Austrian life tables.  
b Effectiveness of statin therapy with respect to morbidity and mortality 
was based on the ScHARR meta-analysis of clinical statin trials.  
b Effectiveness of statin therapy with respect to reduced hospital inter-
ventions was based on Austrian data on the provision of revascularisa-
tion procedures. 
b QALYs were based on data from the ScHARR model.  
b Statin prices were based on Austrian volumes and prices of statins ac-
cording to the social insurance data.  
b Costs of health states:  
o Costs of inpatient care were based on data from the perform-
ance-oriented hospital financing system/LKF (a form of DRG 
system). 
o Costs for outpatient care were calculated according to social 
insurance data (Honorarordnungsdatenbank). 
adaptation of validated 
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The results of the simulation are related to the actual sizes of annual Aus-
trian statin patient cohorts according to social insurance data. The aim was 
to calculate the present aggregated absolute effects of statin therapy for all 
secondary prevention patients who have been prescribed statins since their 
introduction in the Austrian health care system between 1996 and 2006.  
Additionally, for every therapy strategy the model predicts the quality-
adjusted life years gained the cost as well as the incremental cost-utility ra-
tio for a life-time and a 10-year perspective.  
The model will be described in more detail in the following chapters.  
4.2 Therapy Strategies 
The evaluation compares the costs and benefits associated with statin treat-
ment versus no statin treatment. As lipid-regulating drug therapy should be 
combined with advice on diet or lifestyle measures and, if appropriate, other 
risk-reducing measures (e.g. reduction of blood pressure), it is assumed that 
all patients entering the model have been given standard advice regarding 
dietary control and other appropriate measures. The ‘statin group’ addition-
ally receives statins. 
Hence, the decision analytic health economic model compares the following 
therapy strategies: 
1. NoStatin 
 Non-medical lipid-lowering therapy (standard advice only)  
2. Statin 
 Statin therapy according to doses used in trials + standard advice 
4.3 Outcome Parameters and Time Horizon 
Both, medical and economic outcome parameters were calculated. Medical 
parameters were: 
b Clinical events (non-lethal MI, stable and unstable Angina, stroke 
with history CHD), 
b Revascularisation interventions (CABG, PCI), 
b CHD- and cerebrovascular-specific mortality,  
b Quality adjusted life years gained (QALYs). 
 
Economic outcome parameters were: 
b Direct medical costs in Euros (2007 prices or inflated),  
b Discounted incremental cost-utility ratio in Euros per QALY.  
 
Cardiovascular health outcomes were calculated for the years 1997 to 2007 
(11 years). Costs, quality adjusted life-years and cost-utility ratios were cal-
culated for life-time and for a ten-year time horizon. 
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4.4 Perspective 
As the report aims to support decisions of public payers, costs and effects 
were calculated from the perspective of the public payers in the Austrian 
health care system. Thus, only direct costs have been included in the cost 
calculation while indirect costs from lost productivity (due to illness, prema-
ture death and informal care) or costs incurred directly by patients have not 
been taken into account. As shown in chapter 3.3, the latter can be substan-
tial, thus by excluding them we will not be able to demonstrate the overall 
societal costs and potential cost-savings.  
4.5 Discounting 
Guidelines on economic evaluation state that, according to economic theory, 
results from economic evaluations, need to be discounted [e.g.27]. According 
to an Austrian consensus paper on economic evaluations, for the cost-utility 
analyses, a discount rate of 5 % is applied to costs and health benefits re-
spectively [28]. The discount rate is varied between 0 % and 5 % to test for 
uncertainty and to inform decision makers on discounted and undiscounted 
results.  
The calculation of expected population health gains for the years 1997 to 
2007 addresses epidemiological outcomes only and results therefore have not 
been discounted.  
4.6 Model Structure 
Figure 4.6-1 shows the structure used for calculating the outcome parame-
ters. The model is based on annual cycles.  
As described in chapter 3.4.1, the first Austrian guidelines on statin therapy 
for the secondary prevention of CVD state that statins are indicated for pa-
tients with hypercholesterinaemia and manifest CHD (defined as angina, 
MI and status post PCI or CABG). According to these guidelines, in the base 
case, analysis patients can start in three ‘secondary prevention health states’ 
being ‘stable angina’, ‘unstable angina’ or ‘first myocardial infarction’. Per 
definition patients in these health states have experienced the according 
event in the previous year.  
public payer perspective 
discount rate: 5 % 
no discounting for 
epidemiological results 
model structure: 
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Patients who have suffered from stable angina can then either move to ‘un-
stable angina’ or to ‘post stable angina’. Furthermore, they can experience 
their first MI. Patients who start in the health state ‘unstable angina’ (mean-
ing they have experienced unstable angina in the previous year) can either 
move to ‘post unstable angina’ or to ‘first MI’. Finally, patients who start in 
the health state ‘first MI’ can either experience a subsequent MI in the first 
year or they move to the health state ‘no subsequent MI first year’.   
Patients in the health state ‘post stable angina’ can either remain in that 
state, move to ‘unstable angina’ or to ‘first MI’. Similarly, patients in the 
health state ‘post unstable angina’ can remain in that state or move to ‘first 
MI’. Additionally, patients can move to ‘stroke’ from all MI health states. In 
other words, CVD outcomes are only considered for patients with a history 
of MI.  
Finally patients can move to ‘coronary heart disease death’, ‘cardiovascular 
death with history of coronary heart disease’ or ‘death from other causes’ 
from all health states.  
Revascularisation interventions are not directly predicted by the model. 
Thus they have been calculated by relating the model outputs for ‘stable an-
gina’, ‘unstable angina’ and ‘MI’ to the typical patterns of revascularisation 
intervention provision in Austria based on published literature and expert 
opinion (see 4.9 for details). 
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Figure 4.6-1: Model structure 
4.7 Model Parameters 
4.7.1 Transition Probabilities 
Transitions from and to the different health states are based on the 
ScHARR-model (table 4.7-1). UK registries were used to calculate transi-
tional probabilities for patients with manifest CHD (Nottingham Heart At-
tack Register; South London Stroke Register) [29, 30]. Where registry data 
were not available (progression from stable angina to unstable angina, MI or 
CHD death) secondary data from the literature were used [31].   
transition probabilities 
based on UK data 
MI Myocardial Infarction
SA Stable Angina 
USA Unstable Angina
CVD Cardio vascular disease
yr Year
CHD Coronary heart disease
subs Subsequent
comments:
health states 'First MI', 'SA', 'USA' refer to patients who had an event in previous year
health states 'post SA', 'post USA', 'post stroke' refer to patients who have not had an event in previous year
patients can progress to 'fatal CHD', 'fatal CVD history CHD', 'death other cause'  from alll states
patients can progress to 'stroke' from all MI states
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The ScHARR model takes into account that the probability of experiencing 
further events after primary events is strongly correlated with age (for ex-
ample multivariate regression analysis showed that for patients experiencing 
an MI the mean probability of a second event within 1 year is 5.4 % at age 45 
and 29.8 % at age 85). Logistic and multivariate regression analyses of the 
observational data mentioned above were used to retain age specific prob-
abilities which feed into the model [14]. Table 4.7-1 presents the transitional 
probabilities for the untreated population by age.  
Table 4.7-1: Annual transitional probabilities by age in the untreated population 






Angina Non fatal MI Stroke CHD death
CVD death 
history CHD
Markov model health states for age 45
Stable angina 0.0013 0.0032 0.0009
Unstable angina (1st year) 0.4950 0.0362 0.0016
Unstable angina (subs yr) 0.0186 0.0081 0.0004
MI (1st yr) 0.1280 0.0015 0.0167 0.0007
MI (subs yr) 0.0162 0.0004 0.0052 0.0002
Stroke (1st year) 0.0016 0.0459 0.0111 0.0111
Stroke (subs yr) 0.0016 0.0186 0.0049 0.0049
Markov model health states for age 55
Stable angina 0.0029 0.0062 0.0035
Unstable angina (1st year) 0.0497 0.0617 0.0004
Unstable angina (subs yr) 0.0348 0.0100 0.0007
MI (1st yr) 0.1152 0.0032 0.0319 0.0002
MI (subs yr) 0.0179 0.0010 0.0091 0.0013
Stroke (1st yr) 0.0031 0.0459 0.0111 0.0046
Stroke (subs yr) 0.0031 0.0186 0.0049 0.0021
Markov model health states for age 65
Stable angina 0.0060 0.0110 0.0070
Unstable angina (1st year) 0.0488 0.1031 0.0046
Unstable angina (subs yr) 0.0632 0.0119 0.0005
MI (1st yr) 0.1019 0.0068 0.0599 0.0027
MI (subs yr) 0.0185 0.0022 0.0152 0.0007
Stroke (1st yr) 0.0055 0.0423 0.0260 0.0260
Stroke (subs yr) 0.0055 0.0223 0.0104 0.0104
Markov model health states for age 75
Stable angina 0.0091 0.0158 0.0070
Unstable angina (1st year) 0.0466 0.1671 0.0074
Unstable angina (subs yr) 0.1122 0.0139 0.0006
MI (1st yr) 0.0874 0.0141 0.1088 0.0048
MI (subs yr) 0.0178 0.0047 0.0235 0.0010
Stroke (1st yr) 0.0080 0.0446 0.0206 0.0586
Stroke (subs yr) 0.0080 0.0246 0.0206 0.0206
Markov model health states for age 85
Stable angina 0.0122 0.0207 0.0070
Unstable angins (1st yr) 0.0425 0.2587 0.0115
Unstable angina (subs yr) 0.1955 0.0160 0.0007
MI (1st yr) 0.0711 0.0278 0.1875 0.0083
MI (subs yr) 0.0160 0.0091 0.0340 0.0015
Stroke (1st yr) 0.0104 0.0446 0.0185 0.1215
Stroke (subs yr) 0.0104 0.0252 0.1215 0.0375
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4.7.2 Demographic and Clinical Characteristics of 
the Study Population 
In the absence of Austrian prevalence data, distribution of patients into 
primary event states was based on the ScHARR model which used heart dis-
ease registries for this purpose [29]. Distribution into the health states 
changes according to gender and age as shown in Table 4.7-2.  
Table 4.7-2: Distribution into CHD health states for different ages and gender 
 
Background mortality has been adjusted to Austria by using age and gender-
specific death rates from Statistik Austria [32].   
To calculate population health gains for Austria the model was run with and 
without statin therapy for both genders and for each year of age (from age 31 
to 99) separately. These simulation results are then projected to all Austrian 
statin patients. In the absence of age and gender characteristics of Austrian 
patients taking statins, Austrian patients using statins were distributed into 
different ages by applying a gamma distribution based on an expected value 
of 60 and a standard deviation of 8 in the base case. Furthermore, interna-
tional experience [14] has shown that the relation between male and female 
statin taker is 60:40. These parameters were varied in sensitivity analyses 
(see 4.11). 
4.7.3 Effectiveness of Statin Therapy 
In the ScHARR model, a standard meta-analysis based on a systematic lit-
erature review up to the year 2004 was conducted to calculate the relative 
risks of statin therapy for the health states of interest. The results are shown 
in Table 4.7-3. Benefits of statin therapy have been modelled by adjusting 
the probabilities for events in the model with relative risks observed in the 
meta-analysis. The model assumes that the relative risks reported in the tri-
als continue over lifetime since no evidence exists suggesting that the effect 
diminishes over time. The ScHARR meta-analysis did not include data on 
the efficacy of lovastatin. However, as shown in chapter 3.4, this type of 
statin has hardly been prescribed in Austria. Thus, specific efficacy data on 
lovastatin have not been taken into consideration. 
 
 
distribution into health 
states based on UK data 
background mortality 
from Austrian life-tables 
 
age and gender 
characteristics of 
Austrian statin takers 














30 45% 12% 43%
45 47% 16% 36%
55 57% 12% 30%
65 46% 18% 36%








30 46% 12% 42%
45 38% 13% 49%
55 46% 10% 44%
65 41% 16% 43%
75 40% 17% 42%
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Table 4.7-3: Relative risk values and sources 
Health State Mean RR Source 
Stable Angina 0.69 ScHARR RevMan Meta Analysis [14] 
Unstable Angina 0.82 ScHARR RevMan Meta Analysis [14] 
Non fatal MI 0.57 ScHARR RevMan Meta Analysis [14] 
Fatal CHD event 0.72 ScHARR RevMan Meta Analysis [14] 
Non fatal Stroke history CHD 0.66 ScHARR RevMan Meta Analysis [14] 
Fatal CVD history CHD 1.00 ScHARR RevMan Meta Analysis [14] 
 
To check the availability of more recent efficacy data addressing the relevant 
clinical endpoints of cardiovascular morbidity and mortality a systematic 
literature review has been conducted for the years 2004 to 2007 (The search 
strategy and the selection of references are shown in the appendix). The re-
view showed that trial analyses for specific subgroups (gender, patients with 
diabetes) have been published since 2004. However, no publication was 
available which would have required changes in the meta-analysis results 
from ScHARR since these address the general relative risks for the selected 
health states without focussing on specific subgroups. 
4.7.4 Quality of Life Data 
In addition to the illustration of health outcomes in the form of physical 
units (morbidity, mortality), health outcomes are calculated in the form of 
the generic indicator ‘quality adjusted life years’ (QALY). The principle of 
QALYs is that life expectancy and health related quality of life that result 
from the medical technologies under evaluation are combined into a single 
outcome index. QALYS will be used as the denominator in the cost-utility 
analyses in chapter 5.4 (see [27] for more details on the method).  
In order to calculate QALYs, quality of life data (utility values) are required. 
According to methodological standards of cost-utility analysis these data 
may be transferred from one county to another if no country-specific data 
are available [27]. Hence, age-related quality of life data (utility values) for 
the overall population and for the health states under investigation have 
been used from the ScHARR model. These are based on UK data (Table 4.7-
4; Table 4.7-5). 
 
literature update for 
2004-2007: 
 
no changes required 
QALY: 
combines life 
expectancy and health 
related quality of life 
 
data used from UK 
model 
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Table 4.7-4: Utility values by age 
Utility values by age used in the ScHARR cost effec-
tiveness model 
Age (years) utility age utility 
45 0.869 75 0.741 
50 0.848 80 0.72 
55 0.826 85 0.699 
60 0.805 90 0.678 
65 0.784 95 0.656 
70 0.763 100 0.635 
Source: Ward et al. [14] based on secondary literature from Kind et al. [33] 
Table 4.7-5: Utilities for health states 
Utilities for health states  
Health state Utility (mean)  Source 
CHD 
Stable angina 0.808 Ward et al. 2005 [14] based on secon-
dary  literature [34] 
Unstable Angina 0.770  Ward et al. 2005 [14] based on secon-
dary literature [35] 
MI 0.760  Ward et al. 2005 [14] based on secon-
dary literature [35] 
CVD 
Stroke 0.629 Ward et al. 2005 [14] based on secon-
dary literature [36] 
Source: Ward et al. [14] based on secondary literature  
4.7.5 Costs 
Cost calculations are based on Austrian service patterns and unit costs. In-
formation on typical services which are provided for the different health 
states has been obtained from medical experts. Only costs for the health care 
system (direct costs) have been included in the calculation. Costs are at 2007 
prices and inflated where necessary. 
Services for statin treatment as well as for treatment in the different health 
states are provided both in primary and in hospital care. In the absence of 
precise cost data, unit costs for these services are based on reimbursement-
tariffs which are used as a proxy for actual costs. Being aware of their limita-
tions, it is assumed that they roughly represent the magnitude of costs of the 
services analysed. Unit costs for primary care services are based on data 
from the Federation of the Austrian Social Insurance Institutions (database 
on tariffs/Honorarordnungsdatenbank). Unit costs for inpatient services are 
based on data from the Austrian performance-oriented hospital reimburse-
ment system (LKF) which is a form of diagnosis-related-group system 
(DRG). The average LKF points for selected hospital services, adjusted by a 
pre-defined factor that accounts for total costs (for example 1.7 for 2002) 
[37], are used as a proxy for the monetary value of interventions and treat-
only health care system 
costs (direct costs ) 
included 
social insurance tariffs 
for statin treatment 
costs and primary care 
 
hospital reimbursement 
data (LKF) for hospital 
costs 
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ment. Table 4.7-6 gives an overview of the health services included and the 
unit costs applied. The sources used for each category are presented in the 
appendix (chapter 9). 
Overall, service patterns and related unit costs for four different health 
states (stable angina, unstable angina, MI, stroke) have been included in the 
model. For some health states (MI, stroke) first year costs are higher than 
the costs in subsequent years. 
Treatment of stable angina has been calculated to cost on average 860 Euros 
for both first and subsequent years. Basic primary care costs for the treat-
ment of unstable angina are assumed to be the same as for stable angina. On 
average, treatment for myocardial infarction costs 5,265 Euros in the first 
year and 860 Euros in subsequent years. Treatment of stroke has been calcu-
lated to cost 6,381 Euros in the first year and 1,831 Euros thereafter.  
Table 4.7-6: Resource types and unit costs (base case analysis) 
Ergo: Ergometry; ECG: Electrocardiogram; Echo: Echocardiography; Source: Social 
Insurance database on tariffs, LKF-database; own calculation;  
MI and stroke more 
expensive in first year 
stable  angina:        
860 € / year, 
MI 1st  year: 5,300 €  
stroke 1st year: 6,400 €        
Statin treatment Type of resources used 
costs per year 
(weighted 
average)
Medication costs (see following 
table for details) 341
GP visits + Monitoring 287
Health States











subsequent year like 1st year 860
Unstable Angina 1st year Primary care = stable angina 860
subsequent year Primary care = stable angina 860
MI 1st year Hospital costs (average) 4,835
Primary care =stable angina 860
total 5,265
subsequent year Primary care =stable angina 860
fatal event Hospital costs (average) 4,835
Stroke 1 st year Hospital costs (average) 3,897





Primary care (=stable 
angina+neurologist) 1,183
fatal event Hospital costs 3,897
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The annual costs for statin treatment (Table 4.7-7) are based on the overall 
costs spent for each type of statin between 1996 and 2006. A weighted aver-
age of 341 Euros has been calculated according to the proportion each type 
of statin that had been prescribed. Additionally, costs of 278 Euros per year 
for regular GP visits and monitoring have been included. Costs for the han-
dling of potential side-effects of statin therapy have been neglected due to 
their minor significance in clinical studies.  
Full details on services included, unit costs and data sources are provided in 
the appendix. 
Table 4.7-7: Statin costs 
 Source: Social insurance database; own calculations 
 
On the basis of these data, two different types of cost calculations were un-
dertaken:  
Firstly, the budget impact over time with respect to total net costs for the 
Austrian statin population (in comparison to the ‘NoStatin’ group) was as-
sessed (see 5.3.1). Unfortunately, the cost outputs in the model are overall 
aggregate values. A differentiation between statin costs and costs for the se-
lected health states as well as the potential cost containment was therefore 
only possible via a rough estimation.  
While outcomes for each statin cohort have been analysed for the years 
thereafter (e.g. outcomes for statin taker from 1996 are presented from 1997 
onwards for the following 10 years until 2007; see 4.9), cost calculation has to 
reflect that costs were already incurred in 1996. Thus, the budget impact is 
presented for 1996 to 2007 (12 years). Since no data on statin expenditure 
was available for 2007, expenditure from 2006 was extrapolated for one year. 
According to the guidelines for budget-impact analysis [38], results for this 
analysis are presented undiscounted. 
statin treatment  
341 € / year plus 278 € 
regular GP visit 
details in the appendix 




2007 for Austrian statin 
population  
Statin costs per year according to price per daily dose ( €)
year Atorvastatin Fluvastatin Lovastatin Pravastatin Simvastatin Rosuvastatin
1996 0.00 328.73 669.11 444.16 424.74 0.00
1997 404.70 321.38 654.67 421.41 421.96 0.00
1998 414.63 320.68 650.05 416.87 421.21 0.00
1999 414.77 320.68 601.03 415.06 418.91 0.00
2000 407.70 317.93 579.55 408.39 414.22 0.00
2001 405.91 279.78 576.06 400.46 409.13 0.00
2002 402.79 258.42 576.33 400.04 376.60 0.00
2003 394.44 251.76 575.16 399.58 242.15 328.75
2004 351.78 225.00 381.33 336.62 157.05 338.45
2005 334.79 218.28 348.67 214.07 131.45 328.70
2006 302.11 213.83 347.77 149.75 120.26 330.23
Average (€)
383.36 277.86 541.79 364.22 321.61 331.53
Proportion of total prescriptions (%)
25 11 1 13 49 1
Weighted average for all types between 1996 and 2006 (€)
340.96
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The second type of cost calculation is an analysis of life-time costs per per-
son for the statin and the ‘NoStatin’ group. This is again based on the model 
outputs and will be used in order to calculate incremental cost-utility ratios. 
According to the guidelines on economic evaluation [27], results are pre-
sented discounted and undiscounted (see 5.3.2).   
4.8 Calculation of the Cohort Sizes 
As has been outlined in chapter 2, one aim of the study is to estimate the 
population-wide health gains that can be expected from the use of statins be-
tween 1996 and 2006 in Austria. This requires relating the model results 
from fictitious cohorts of various ages and gender to the actual number of 
patients who have taken statins in the observed time period.  
Chapter 3.4.2 details how many statins were been prescribed between 1996 
and 2006. In the absence of more precise data on the actual number and 
demographic characteristics of patients who have been prescribed these 
drugs, the number of patients was calculated with the following approach: 
Firstly, the total number of daily doses (DDD) was calculated from the total 
number of prescribed statins for each year according to the defined daily 
dose. Secondly, the total daily doses were divided by 365 in order to obtain 
an estimation of the annual total number of patients who could in theory 
have taken statins while assuming that they took the statins regularly over 
the entire year. However, this assumption is varied in sensitivity analysis. It 
is furthermore assumed that once a patient starts taking statins in secondary 
prevention, medication lasts life-long. Thus, in order to estimate the number 
of patients who start taking statins each subsequent year of interest, the 
number of patients from previous years is subtracted.  
Additionally, calculations have taken into account that some of the initial 
patients will die throughout the 11-year period of observation resulting in 
changes in the subsequent cohort sizes. Hence, the annual number of ‘new 
statin takers’ was adjusted to take into consideration those who have died. 
The probability of dying was based on the model outputs for the statin co-
hort using the results from the health states ‘CHD death’, ‘CVD 
death/history CHD’ and ‘death other cause’. Half-cycle corrections were 
conducted to account for the fact that patients die continuously throughout 
the year and not necessarily at the end of a cycle.  
4.9 Calculation of Population Health Gains  
The model predicts results for various cardiovascular health states and fatal 
events of interest. As specified in chapter 4.6, these are ‘stable angina’, ‘un-
stable angina’, ‘first MI’, ‘subsequent MI in first year’, ‘stroke/history CHD’, 
‘CHD death’ and ‘CVD death/history CHD’. Outcomes are predicted for un-
treated and for treated cohorts for various ages and for males and females 
separately. Model outputs for stable angina, unstable angina and MI repre-
sent the total number of persons in the health state of interest. In epidemiol-
ogical terms, this corresponds to the prevalence for these health states. On 
life time cost per person 
for statin and ‘NoStatin’ 
group 
calculation of cohort 
size: 
no patient-level data 
available, thus… 
…calculation of  total 
number of daily doses 
from number of 
prescribed statins, 
 
division by 365, 
taking into account that 
patients die, 
 
calculation of mortality 
adjusted ‘new statin 
takers’ per year 
calculation of 
population health gains 
for: 
prevalence of stable 
angina, unstable angina, 
myocardial infarction 
incidence of fatal events 
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the contrary, fatal events are predicted as new events occurring, thus indicat-
ing incidence. 
For each year of age as well as for males and females the model results for 
the first 12 years with and without statin treatment were used for further 
calculations: The age and gender specific results from the model were mul-
tiplied by the probabilities of being in the various ages (these have been ob-
tained by gamma-distribution as explained in chapter 4.7.2). This yielded 
the Austrian age and gender specific probabilities for each health states of 
interest and the probabilities of experiencing a fatal event.  
Next, for each health state and fatal event the prevalence or events per per-
son for the years 1 to 12 was calculated by aggregating the corresponding re-
sults from each year of age (described in the previous paragraph). The re-
sults of this calculation – adjusted by half-cycle correction – represent the 
total prevalence for the health states and the occurrence of events per per-
sons for 11 years (1997 to 2007). 
In the following step, the number of persons in each year’s Austrian cohort 
was multiplied by the prevalence and fatal events per person. The cohort 
from 1996 can benefit from treatment for 11 years while the cohort starting 
in 2006 can only benefit from one year of treatment. In other words, for each 
cohort, outcomes were taken into account from the subsequent years on-
wards (for example, for the 1996-cohort outcomes from 1997 to 2007 were il-
lustrated). 
Finally, the total number of persons in each health state of interest and the 
total number of events were summarised for each year. Total health gains 
were estimated by calculating the differences in outcomes between the 
treated and the untreated group.   
Besides the health states and fatal events mentioned, some additional out-
come parameters not directly predicted by the model are relevant. These are 
‘fatal MI’ and ‘revascularisation interventions’.  
The number of fatal MIs was calculated by applying the gender specific pro-
portions of fatal MIs from all CHD deaths in Austria. The figures used were 
based on mortality data from Statistik Austria showing that from all CHD 
deaths in Austria between 1995 and 2007 MIs accounted on average for 45 
%. This corresponds to 53 % and 39 % in males and females respectively 
[39].  
The calculation of the number of revascularisation interventions was based 
on the revascularisation intervention patterns in Austria according to secon-
dary data and expert information. Table 4.9-1 shows the parameter values 
used to calculate the number of PCIs and CABGs in patients with stable an-
gina, unstable angina or MI.  
 
first: calculation of age 
and gender specific 
model outputs for year 1 
to 12  
second: calculation of 
CVD prevalence and 
occurrence of fatal 
events per person + 
half-cycle correction 
third: multiplying the 
results per person with 
annual cohorts 
fourth: summarising the 
results for each health 
state and year 
additionally: calculation 
of fatal MIs and 
revascularisations 
MI based on gender 
specific MI proportion in 
Austria 
revascularisation based 
on utilisation patterns 
(expert info) 
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Table 4.9-1: Revascularisation interventions in Austria 
Source: secondary literature; expert interviews 
* 33 % receive PCI within 6 months [40]; later on no further PCI; within 8 months 17 % of 
patients received CABG in Austria [40]; overall no more than 20 % of patients re-
ceive CABG within year 1 -> for model:  estimation that  18 % receive CABG in 
year 1 
** Within 4 weeks of SA diagnosis 8 % have PCI and 8 % have CABG planned or per-
formed [41]; in total no more than 10 % receive PCI and max. 5 % receive CABG 
in year 1 -> for model: estimation that 7 % receive PCI and 3.5 % receive CABG 
in year 1 
*** 80 % receive revascularisation; from those 80 % receive PCI and 20 % CABG 
# no further PCI is performed and CABG is almost negligible (= 1 in 1000);  
## 5 to 10 % receive revascularisation in year 2 -> estimation in model: 7.5 % receive PCI 
and 7.5 % receive CABG in year 2 
### all of those remaining (if technically possible) receive revascularisation procedure 
(10 % remain without revasc.) 
§ compared to first MI slightly fewer PCI and slightly more CABGs 
4.10 Model Validation 
Extensive model validation had already been carried out for the original 
model. Thus, it is assumed that the model is valid with respect to technical 
and internal validity. For external validation model results were contrasted 
with epidemiological data. As this issue has been addressed as a separate re-
search question in a subsequent project, the results have been presented in 
the corresponding report [42]. 
 
internal, technical and 
external validation 
Interventions post event 
State PCI in % CABG in %
(first) MI* 33 18
SA** 7 3.5
USA*** 65 15
post MI # 0 0
post SA## 7.5 7.5
post USA ### 8 2
subs MI 1st year § 30 21
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4.11 Sensitivity Analysis 
In the original model, extensive sensitivity analyses had been performed to 
account for uncertainty. Both one-way (varying each parameter one at a 
time) and probabilistic sensitivity analyses were performed. In detail, for 
secondary prevention, the influence of statin costs, health state costs, dis-
count rate, utilities, relative risks of statin treatment, compliance (defined as 
the extent to which the medication is taken each day as prescribed), inci-
dence/prevalence of CVD and timeframe of the model on the cost-
effectiveness results have been tested.  
The results showed that statin costs, discount rate and the model timeframe 
had the biggest influence on the results: Higher statin costs, a higher dis-
count rate and a shorter model timeframe increased the cost-utility ratios 
noticeably, while the model was robust to changes in relative risks, cost of 
health states, health state utilities and assumptions on incidence, prevalence 
and compliance [14].  
On the basis of these results the following univariate sensitivity analyses 
were performed for the ‘Austrian model’:  
Firstly, the influence of health state costs, statin costs, discount rates and 
compliance on the cost-utility ratios were tested because these have either 
been changed in the Austrian model or/and have shown to have a significant 
influence in the British model. The model time-frame, which has also 
proven to have considerable bearing on the results in the ScHARR model, 
has been addressed as a separate research question and therefore has been 
presented under the base case results in chapter 5.4. 
The effect of compliance was tested in further analyses: First, since reduced 
compliance (in the form of not picking up prescriptions) may mean that 
more patients would have been able to receive statins from the overall num-
ber of prescribed statins, the impact of compliance on cohort size was ana-
lysed. Based on data on total prescribed doses of statins, the number of per-
sons who would have been able to take statins was calculated assuming  dif-
ferent compliance scenarios according to the evidence from the UK [14] (see 
chapter 5.5). Second, how this impacts on the results in terms of population 
health gains has been evaluated.  
Finally, the applied age and gender distribution of Austrian statin patients 
was varied to assess its effects on the results in terms of cohort size and 
population health gains. The distribution was varied according to the age 
and gender distribution in hospital discharge data for myocardial infarction 
because these are considered to be representative for persons who take stat-
ins.  
4.12 Software 
The original model has been calculated with Microsoft EXCEL. This soft-
ware has also been used for the adapted version. 
 
sensitivity analysis in 





statin costs, discount 
rate and model 
timeframe had greatest 
influcence 
sensitivity analysis in 
adapted model: 
influence of health state 
costs, statin costs, 
discount rates and 
compliance on cost-
utility, 
effect of compliance on 
cohort size and health 
gains, 
effect of gender and age 
of statin takers on 
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5 Results 
5.1 Cohort Size 
Table 5.1-1 shows the results from the cohort size calculation as described in 
chapter 4.8. Column two represents the total number of daily doses based on 
prescribed statins and defined daily doses. The figure rises from 13 million 
to around 171 million daily doses in 2006.  
Column three shows the total number of patients when all take statins regu-
larly throughout a year. Hence around 35,600 patients started taking statins 
in 1996. In 2006, the total number of patients would have increased more 
than tenfold to around 468,000. Column four shows the number of new pa-
tients per year taking statins which rose from 35,600 to 74,700.  
In column five, the amount of new patients per year have been adjusted to 
reflect mortality meaning that annual cohorts are in fact slightly greater in 
number. According to the base case calculation, 36,300 persons started tak-
ing statins in 1996. In 2006, there were almost three times more persons 
(108,000) starting statin therapy. Overall, there would have been almost 
600,000 persons who had taken statins between 1996 and 2006 including 
those who died. This corresponds to around 7.5 % of the Austrian popula-
tion. 
Table 5.1-1: Cohort size 
 
Year
Total DD for 
















1996 13,008,421 35,640 35,640 36,257 36,257
1997 20,511,480 56,196 20,556 22,035 58,293
1998 34,051,918 93,293 37,097 39,799 98,092
1999 49,334,692 135,164 41,871 46,571 144,663
2000 61,699,193 169,039 33,875 40,166 184,829
2001 73,682,604 201,870 32,831 40,559 225,388
2002 88,031,836 241,183 39,313 49,445 274,834
2003 109,392,667 299,706 58,523 73,301 348,135
2004 126,826,414 347,470 47,764 66,767 414,901
2005 143,489,059 393,121 45,651 67,522 482,424
2006 170,753,792 467,819 74,698 108,024 590,448  
Source: Social insurance data, own calculations; DD: daily dose 
 
overall daily doses 
increased from 13 to 171 
million 
annual patients 
(unadjusted) rose from 
35,000 to 74,700 
mortality adjusted 
number rose from 
36,300 to 108,000 
 
in total: ˜ 600,000 over 
11 years 
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5.2 Effectiveness of Statin Therapy 
5.2.1 Expected Health Gains for Austrian Patients 
from 1997 to 2007  
Prevalence of Angina, MI and Stroke 
Table 5.2-1 compares statin treatment with no statin treatment for the 
health states stable angina, MI and stroke showing the absolute annual 
amount of persons for each. Health gains are displayed as absolute differ-
ences between the untreated and treated population.  
In terms of stable angina, the model actually predicts an increase for the 
statin group. This is because patients who do not take statins progress more 
quickly to more severe health states. 
Furthermore, the model estimates that in the 36,000 persons who took stat-
ins in 1996, 52 cases of unstable angina occurred in 1997 compared with 64 
cases if these persons had not taken statins. Hence, there were 11 fewer cases 
of experienced unstable angina in 1997. The health gains from taking statins 
continuously increased resulting in minus 175 fewer cases in 2007 in around 
108,000 patients who took statins in 2006.  
In terms of MI, in the 36,000 persons who took statins in the first year, 755 
cases of MI occurred in 1997 compared with 1,354 if these persons had not 
taken statins. Consequently, there were 599 fewer cases of MI due to statins 
in 1997. In 2007, 5,234 fewer MIs occurred as the amount of persons using 
statins increased. However, the model also predicted that despite taking stat-
ins, around 7,100 MIs in 108,000 statin takers occurred in 2007. 
Finally, whereas the model predicted for 1997 that 56 cases of stroke occured 
in patients with a history of CHD without statins, it foresaw 39 stroke cases 
for those on statins. Thus, strokes were reduced by 17 in the first-year co-
hort. In 2007, statin treatment resulted in 239 fewer strokes in patients with 
a history of CHD. Yet, around 490 strokes were estimated despite taking 
statins compared to 725 strokes in the untreated cohort in 2007. 
Overall, by 2006, around 600,000 persons were estimated to have taken stat-
ins over 11 years. In these, 28,600 fewer cases of unstable angina (860), MI 
(26,600) or stroke (1,100) and roughly 6,100 more cases of stable angina oc-
curred. In other words, 21 persons had to be treated with statins in order to 
avoid or postpone one patient going into a CVD health state. At the same 
time, about 42,000 cases of unstable angina (4,400), MI (35,200) or stroke 
(2,300) occurred despite statins. 
 
prevalence of angina, 
MI and stroke: 
more cases of stable 
angina in statin group 
USA 2007: minus 175 
cases in 108,000 statin 
takers 
MI 2007: minus 5,200 
cases in 108,000 statin 
takers   
7,100 MIs still occurring 
in 2007 
strokes 2007: minus 240 
cases  
overall: 28,600 fewer 
CVD cases in  600,000 
statin takers in 11 years 
number needed to treat: 
21 
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Table 5.2-1: Absolute number of cases in different health states in ‘Statin’ and 
‘NoStatin’ group 
MI: myocardial infarction; SA: stable angina; USA: unstable angina;  
 
Figure 5.2-1 shows the changes in the health states of interest graphically. 
Figure 5.2-1: Differences in cardiovascular health states between ‘Statin’ and 
‘NoStatin’ group (absolute numbers) 
MI: myocardial infarction 
 
As shown in Figure 5.2-2, more health gains are observable in men than in 
women. The gender difference is largest with respect to the number of per-





more health gains in 


























1997 15923 16306 107 64 52 -11 1354 755 -599 56 39 -17
1998 25525 25890 243 104 86 -18 1531 843 -688 69 47 -23
1999 42395 43251 476 176 146 -31 2560 1428 -1132 118 80 -38
2000 61954 63274 807 262 217 -45 3540 1979 -1560 169 114 -55
2001 78393 79959 1211 338 281 -57 4126 2320 -1805 207 139 -68
2002 94385 96399 1694 416 347 -69 4620 2604 -2016 253 170 -83
2003 113551 116395 2280 510 426 -84 5834 3325 -2509 316 212 -104
2004 142123 146584 3029 647 541 -106 7573 4322 -3250 413 278 -136
2005 167922 173064 3896 774 649 -125 8615 4933 -3681 489 328 -162
2006 193154 199230 4893 904 760 -144 9747 5615 -4132 574 384 -190
2007 232053 242723 6115 1105 930 -175 12359 7125 -5234 725 487 -239
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Figure 5.2-2: Gender specific differences for angina, MI and stroke between 
‘Statin’ and ‘NoStatin’ group (absolute numbers) 
MI: myocardial infarction; SA: stable angina; USA: unstable angina 
Fatal Events 
Table 5.2-2 shows the absolute number of fatal events for the two treatment 
alternatives according to the model results. While the model demonstrates 
that 763 patients from around 36,000 would have died of CHD without 
statin treatment in 1997, treatment reduced fatal CHD events to 539 which 
corresponds to 224 fewer CHD deaths. Furthermore, the model shows that 
in 2007, comparing those on no medication to the 108,000 estimated statin 
takers, 2,061 fewer persons died of CHD. However, around 4,900 died of 
CHD despite taking statins.  
From all CHD deaths avoided or postponed, 107 and 982 are related to fatal 
MI in 1997 and 2007 respectively.  
Furthermore, the model shows that health gains with respect to fatal cere-
brovascular diseases for patients with a history of CHD are considerably 
lower than for fatal CHD. In the first year of observation, almost no differ-
ence between taking statins and not taking statins can be observed. In 2007, 
26 fewer patients died in the statin group.  
Overall, by 2007, a total number of around 600,000 patients who were esti-
mated to have taken statins between 1996 and 2006 can be weighed against 
10,300 avoided/postponed fatal CVD events. Put differently, 59 persons had 
to take statins between 1996 and 2006 in order to avoid or delay one fatal 
CVD event. Despite statin treatment 24,000 fatal CHDs and 1,400 fatal 
cerebrovascular events occurred. 
 
fatal CVD events: 
 
2007: minus 2,700 fatal 
CHDs in 108,000 statin 
patients 
 
fatal MI 2007: minus 
980 
cerebrovascular death: 
almost no benefit 
in total: 10,300 fewer 
fatal events 
number needed to treat: 
59 
Absolute gender specific differences in angina, MI and stroke between 
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Table 5.2-2: Absolute number of fatal events in treated and untreated population 
CHD: coronary heart disease; cerebrov. death: cerebrovascular death; MI: myocardial 
infarction; untreat.: untreated 
 
Figure 5.2-3 presents the reduction in fatal events graphically. 
Figure 5.2-3: Difference in fatal events between ‘Statin’ and ‘NoStatin’ group 
(absolute numbers) 
























1997 763 539 -224 33 32 -1 365 258 -107
1998 805 560 -246 35 33 -2 385 268 -118
1999 1375 963 -412 59 56 -3 657 460 -197
2000 1893 1324 -569 82 77 -5 905 633 -272
2001 2197 1534 -662 96 89 -7 1050 733 -316
2002 2589 1812 -778 114 106 -8 1236 865 -371
2003 3175 2225 -950 142 131 -11 1516 1063 -453
2004 4167 2924 -1243 187 173 -14 1989 1396 -592
2005 4747 3328 -1419 216 199 -17 2265 1588 -676
2006 5422 3806 -1616 250 229 -21 2585 1816 -769
2007 6947 4886 -2061 321 295 -26 3312 2330 -982
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Similar to the numbers of angina, MI and stroke more fatal events are 
avoided in men than in women (Figure 5.2-4). 
Figure 5.2-4: Gender specific differences in fatal events between ‘Statin’ and 
‘NoStatin’ group (absolute numbers) 
CHD: coronary heart disease; Cerebrov. death: cerebrovascular death; MI: myocardial 
infarction 
Revascularisation 
Since revascularisation procedures are closely linked to the diagnosis of an-
gina or MI, reduced occurrence of these types of coronary heart disease will 
probably result in reduced numbers of revascularisation procedures. 
As Table 5.2-3 demonstrates, health gains obtained from statins result in a 
reduction of both, PCI as well as CABG in the model. Compared to ‘no 
statin’ in ‘statin takers’ 162 fewer PCIs and 110 fewer CABGs were per-
formed in 1997. In 2007, 632 PCIs and 447 CABGs were avoided according 
to the base case analysis in the model. However, despite statins, the per-
formance of 1,800 PCIs and 1,500 CABGS was estimated for 1997 and deliv-
ery of 25,750 PCIs as well as 20,200 CABGs was predicted for 2007. 
The number of revascularisation interventions avoided is low compared to 
health gains in MI described earlier. However, since the number of stable 
angina increases and revascularisation interventions are also provided for 
people with stable angina the overall reduction in revascularisation inter-
ventions is predicted to be low in the model. 
Overall, by 2007, a total number of around 600,000 patients who were esti-
mated to have taken statins between 1996 and 2006 can be weighed against 
around 7,000 revascularisation interventions avoided corresponding to treat-
ing 86 patients in order to avoid one revascularisation intervention. 231,000 
revasculariation interventions were carried out in spite of statin treatment in 
the same time period. 
fewer fatal events in 





…and shown in model, 
however… 
overall reduction in 
revascularisation 
interventions low 
86 patients to be 
treated to avoid one 
revascularisation 
intervention 
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Table 5.2-3: Absolute number of revascularisation interventions in treated and 
untreated population 
CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention 
 
The reduction is also demonstrated in Figure 5.2-5 
Figure 5.2-5: Difference in revascularisation interventions between ‘Statin’ and 
‘NoStatin’ group (absolute numbers) 















1997 1992 1830 -162 1578 1469 -110
1998 2959 2794 -165 2368 2255 -112
1999 4929 4669 -260 3948 3771 -177
2000 7124 6790 -334 5719 5491 -228
2001 8857 8515 -342 7133 6897 -236
2002 10582 10231 -350 8541 8297 -244
2003 12735 12349 -387 10290 10020 -271
2004 16079 15585 -495 12991 12644 -346
2005 18826 18332 -494 15235 14887 -348
2006 21545 21064 -482 17460 17118 -342
2007 26374 25742 -632 21360 20913 -447
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Figure 5.2-6 demonstrates the reduction in revascularisation interventions 
for males and females. Again, a higher number of interventions are avoided 
in males than in females. 
Figure 5.2-6: Gender specific differences in revascularisation interventions 
between ‘Statin’ and ‘NoStatin’ group (absolute numbers) 
CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention 
5.2.2 Life-time Effectiveness  
In addition to the 11-year health gains in terms of population health, life-
time effectiveness of statin therapy in terms of QALYs has been calculated. 
In contrast to the previous results, gains in QALYs are presented in the form 
of individual averages per person included. This enables better comparison 
with international results.  
Table 5.2-4 and Table 5.2-5 show the discounted and undiscounted life-time 
effectiveness in terms of QALYs per person for different ages. Compared to 
not taking statins, the gain in QALYs for the statin cohort in the model is 
highest for the youngest age groups and decreases with increasing age. The 
average gain in undiscounted QALYs for male statin taker is 1.13 (13.6 qual-
ity adjusted life months) per person at the age of 45. Undiscounted QALYs 
gained per male person decrease to 0.27 (3.2 quality adjusted life months) at 
the age of 85. Females gain on average 1.32 undiscounted QALYs (15.8 qual-
ity adjusted life months) per person at the age of 45 and 0.31 QALYs (3.7 
quality adjusted life months) at the age of 85.  
 
reduction of 
interventions higher in 
males than in females 
QALYs for life-time 
effectiveness 
average quality adjusted 
life months gained  per 
person (undiscounted): 
3.2 to 13.6 (males); 3.7 to 
15.8 (females)  
Absolute gender specific differences in revascularisation interventions 
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Table 5.2-4: Life-time quality adjusted life years gained per person in different 
ages (undiscounted) 
NoStatin: no statin therapy; Statin: statin therapy; QALYs: quality adjusted life years 
 
As expected, QALY values are lower when discounting is applied (table 5.2-
5). They range from 0.37 incremental discounted QALYs in males aged 65 to 
0.21 incremental discounted QALYs in men aged 85 (4.07 to 2.51 quality ad-
justed life months). In females, the values range from 0.44 incremental dis-
counted QALYs in 65 years old women to 0.20 incremental discounted QA-
LYs in 85 years old (4.19 to 2.35 quality adjusted life months).  
Table 5.2-5: Life-time quality adjusted life years per person in different ages 
(discounted at 5 %) 
NoStatin: no statin therapy; Statin: statin therapy; QALYs: quality adjusted life years 
5.3 Costs of Statin Therapy  
As described in chapter 4.7.5, two different types of cost calculations have 
been undertaken: First, the budget impact over time for the Austrian statin 
population (in comparison to the ‘NoStatin’ group) has been assessed (see 
5.3.1). Second, in order to calculate cost-utility ratios, life-time absolute and 
incremental costs (discounted and undiscounted) per person for the statin 
and the ‘NoStatin’ group have been computed (see 5.3.2).   
discounted quality 
adjusted life months: 
2.51 to 4.07 (males); 2.35 
to 4.19 (females) 









Male 45 19.34 20.48 1.13
55 13.87 14.79 0.92
65 8.98 9.70 0.72
75 5.29 5.76 0.47
85 2.63 2.90 0.27
Female 45 21.80 23.11 1.32
55 16.12 17.22 1.10
65 10.43 11.34 0.92
75 6.36 6.95 0.58








Male 45 10.20 10.54 0.34
55 8.30 8.66 0.36
65 6.12 6.49 0.37
75 4.07 4.37 0.31
85 2.25 2.46 0.21
Female 45 10.88 11.23 0.35
55 9.15 9.53 0.39
65 6.81 7.25 0.44
75 4.18 4.47 0.29
85 2.34 2.53 0.20
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5.3.1 Population Costs (Budet Impact) 
Although it has been shown in chapter 5.2.1 that statin treatment seems to 
results in some health gains (especially in the case of MIs and CHD death), 
overall costs are higher in the statin group than in the ‘NoStatin’ group. 
Hence, additional costs from statin treatment cannot be totally compensated 
by cost savings elsewhere.  
Figure 5.3-1 shows that the total net costs in the treated cohort have risen 
from 33 million Euros in 1996 to around 680 million Euros in 2007. If the 
same cohort had been untreated, costs would have been 16 million Euros in 
1996 and roughly 470 million Euros in 2006. The reason for the overall cost 
increases is the annual growth cohort size.  
Figure 5.3-1: Total costs in treated and untreated cohort (in million €) 
 
Figure 5.3-2 shows the estimated net costs for the treated cohort disaggre-
gated into costs for statins and net costs for treating the various CVD condi-
tions. The third category shows the potential cost containment for each year 
in terms of health state costs.  
From total net costs of 33 million Euros in 1996, 17 million Euros were re-
lated to statins and 16 million Euros to costs for treating the CVD health 
states under evaluation. Potential cost-containment is shown to have begun 
in 1997, when reduced cardiovascular events resulted in cost reduction of 8 
million Euros. Total net costs rose to 673 million Euros in 2007 from which 
76 million Euros were related to statin treatment and 597 million Euros to 
health state costs. Potential cost containment is estimated to have been 105 
million Euros by then.  
In comparison to total net costs, cost containment seems comparably low. 
However, as shown in chapter 5.2.1, for some health conditions, the number 
of cases is actually increasing and therefore consuming some of the savings 
made elsewhere. Furthermore, as mentioned, several persons are taking stat-
ins in order to gain the benefit of one event avoided, leaving less room for 
cost containment.  
statin treatment results 
in health gains but… 
…costs can´t be 
compensated by saving 
costs elsewhere 
 
increasing cohorts cause 
increasing costs 
disaggregated costs for 
treated cohort: 
1996: 17 million € statin 
costs + 33 million € 
health state costs 
2007: 76 million € statin 
costs + 600 million € 
health state costs, 105 
million € savings 
savings are partly 
consumed by increasing 
demand elsewhere 




































total costs in untreated cohort total costs in treated cohort
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Figure 5.3-2: Total costs and potential cost containment in treated population 
5.3.2 Lifetime Costs for Cost-Utility Analysis 
Table 5.3-1 and Table 5.3-2 show the undiscounted and discounted costs per 
person for the statin group compared to the ‘NoStatin’ group. Undiscounted 
incremental costs are highest in the youngest age group of 45 accounting for 
16,700 Euros and 18,200 Euros for males and females respectively. They de-
crease to 2,900 Euros in 85 year old males and to 3,200 Euros in 85 year old 
females.  
Table 5.3-1: Lifetime costs per person undiscounted (in €) 
NoStatin: no statin therapy; Statin: statin therapy;  
 
The same pattern relates to discounted costs. Incremental discounted costs 
are 7,900 Euros for males aged 45 and 2,400 Euros for males aged 85. The 
corresponding figures for females are 8,000 Euros and 2,500 Euros respec-
tively. 
undiscounted lifetime 
costs: males: 2.900 to 
16.700 €; females: 3.200 
to 18.200 € 
discounted lifetime 
costs: lower but same 
pattern 
Total costs and potential cost containment in treated 
population (in million €)









































Male 45 30,148 46,827 16,679
55 22,990 35,138 12,148
65 16,694 25,227 8,532
75 11,403 16,749 5,346
85 7,236 10,130 2,895
Female 45 33,472 51,692 18,220
55 26,117 39,646 13,529
65 19,140 28,989 9,848
75 13,038 19,152 6,114
85 7,946 11,192 3,246
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Table 5.3-2: Lifetime costs per person discounted at 5 % (in €) 
NoStatin: no statin therapy; Statin: statin therapy;  
5.4 Cost-Utility Analysis 
Table 5.4-1 shows the costs, QALYs and cost-utility results for the base case 
analysis discounted at a rate of 5 % for different ages and gender. Results are 
presented as averages per person.  
As shown in chapter 5.3.2, in comparison with no statin therapy, statin ther-
apy results in discounted incremental costs between 2,400 Euros and 7,800 
Euros for males and between 2,500 Euros and 8,000 Euros for females. In-
cremental costs decrease with age in both males and females. 
Additionally, it was demonstrated in chapter 5.2.2 that average discounted 
QALYs gained per person due to statins compared with ‘NoStatin’ range 
from 0.21 to 0.37 (2.51 to 4.07 quality adjusted life months) in males and 
from 0.20 to 0.44 (2.35 to 4.19 quality adjusted life months) in females.   
Discounted incremental cost-utility-ratios (ICUR) range from around 11,400 
Euros per QALY to 23,200 Euros per QALY for males and from 12,500 Eu-
ros per QALY to 23,000 Euros per QALY for females. ICURs decrease with 
increasing age. In other words, depending on the age of the patients, be-
tween 11,400 Euros and 23,200 Euros are required to gain one extra QALY 




males: 2,400 to 7,900 € 
females: 2,500 to 8,000 
€ 
discounted QALYs: 
males: 0.21 to 0.37  
females: 0.20 to 0.44         
 
 
ICUR: males: 11,400 to 
23,200 €/QALY 









Male 45 15,662 23,539 7,877
55 13,673 20,281 6,608
65 11,455 16,815 5,360
75 8,931 12,795 3,864
85 6,355 8,731 2,376
Female 45 16,105 24,161 8,056
55 14,418 21,312 6,894
65 12,458 18,317 5,859
75 8,942 12,886 3,944
85 6,287 8,732 2,445
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Table 5.4-1: Base case analysis: discounted incremental costs, QALYs and ICUR 
per person (discount rate: 5 %) for different ages and gender 
ICUR: incremental cost-utility ratio; NoStatin: no statin therapy; Statin: statin ther-
apy; QALYs: quality adjusted life years;  
 
The results differ considerably when a 10-year time horizon is considered. 
While in 85-years-olds, ICURs are similar to the base case analysis, Table 
5.4-2 shows that ICURs are rising significantly in the younger age groups for 
which 65,600 Euros have to be paid per extra QALY gained in males aged 45 
and 74,000 Euros per extra QALY gained in females aged 45. This is around 
three times more than in the base case. 
 
Table 5.4-2: 10-year time horizon analysis: discounted incremental costs, QALYs 
and ICUR per person (discount rate: 5 %) for different ages and 
gender 
ICUR: incremental cost-utility ratio; NoStatin: no statin therapy; Statin: statin ther-
apy; QALYs: quality adjusted life years; 
 
much higher ICURs for 






Male 45 7,877 0.34 23,217
55 6,608 0.36 18,228
65 5,360 0.37 14,400
75 3,864 0.31 12,633
85 2,376 0.21 11,366
Female 45 8,056 0.35 23,057
55 6,894 0.39 17,800
65 5,859 0.44 13,311
75 3,944 0.29 13,803






Male 45 3,867 0.06 65,578
55 3,621 0.09 40,464
65 3,408 0.15 23,132
75 2,983 0.19 15,664
85 2,207 0.18 11,931
Female 45 3,777 0.05 73,903
55 3,535 0.07 47,309
65 3,443 0.15 23,120
75 3,029 0.19 15,684
85 2,266 0.17 13,180
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5.5 Sensitivity Analysis 
As has been mentioned in chapter 4.11, first, the influence of health state 
costs, statin costs, discount rates and compliance on the cost-utility ratios 
were tested. These had either been changed in the Austrian model or/and 
had shown a significant influence in the British model. The results of the 
one-way sensitivity analysis are presented in Table 5.5-1.  
Similar to the British model, increasing or reducing health state costs by 20 
% had only a marginal influence on the ICURs. The influence is bigger 
when statin costs are decreased, especially in the younger ages and at a re-
duction of 40 %. In both cases ICUR decreases by around 30 %, thus becom-
ing more favourable. As expected, discounting has also a considerable influ-
ence. Particularly in the younger age groups, lower discount rates result in 
lower ICURs of up to minus 40 % because of the longer time period these 
persons take statins.  
Finally, the influence of compliance on the ICUR is tested. The UK analysis 
has shown that when lower rates of compliance are accompanied by lower 
costs of treatment with patients failing to pick up their prescriptions, the 
impact on cost-effectiveness is limited [14]. Thus, for the Austrian sensitiv-
ity analysis the worst case of patients collecting prescriptions but failing to 
take the medication (thus incurring full costs) is assumed for two different 
compliance scenarios according to the evidence from the UK-analysis [14] 
(see Table 5.5-2). Sensitivity analysis shows some impact in the younger age 
groups. Generally, the lower the compliance the higher are the ICURs with a 
maximum of plus 48 %.   
In summary, even the highest ICURs in sensitivity analyses do not exceed 
35,000 Euros per QALY. 




 Min Max Min Max 
  €/QALY 
 Sex Male Male Female Female 
 Age 85 45 85 45 
 Base case 11,366 23,217 12,508 23,057 
Health state 
costs 
     
 + 20 % 11,089 23,035 12,212 22,921 
 - 20 % 11,644 23,399 12,804 23,193 
Statin costs      
 - 20 % 9,726 20,134 10,716 19,884 
 - 40 % 8,086 17,051 8,924 16,711 
Discounting      
 No dis-
counting 
10,755 14,726 11,832 13,830 
 Discount 
rate 1 % 
10,878 16,144 11,968 15,302 
 Discount 
rate 3 % 
11,123 19,418 12,239 18,814 
Compliance      
 Scenario 1 13,829 30,144 15,177 30,006 
 Scenario 2 15,020 34,111 16,473 34,023 
sensitivity analysis 
tested health state and 
statin costs, discount 
rate + compliance 
biggest influence: statin 
costs and discount rate 
compliance: higher ICUR 
in lower age groups 
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Table 5.5-2: Compliance in different scenarios 




1 0.90 0.85 
2 0.80 0.78 
3 0.78 0.70 
4 0.75 0.66 
5 0.75 0.65 
all subsequent 
years 
as year 5 as year 5 
 *defined as the extent to which the medication is taken each day as prescribed; 
Source: Ward et al. [14] 
 
Second, two further factors of compliance are reviewed – the influence of 
compliance on cohort size and how this effects results in terms of population 
health. The compliance scenarios chosen are the same as described above 
(Table 5.5-2). 
Based on the compliance rates in scenarios 1 and 2, cohort sizes have been 
adjusted resulting in the following mortality adjusted numbers of annual 
statin patients (Table 5.5-3). 









1996 35,640 36,257 38,101 39,097 
1997 56,196 22,035 27,113 28,367 
1998 93,293 39,799 46,994 48,321 
1999 135,164 46,571 56,446 60,679 
2000 169,039 40,166 52,263 57,183 
2001 201,870 40,559 53,211 59,356 
2002 241,183 49,445 62,880 70,060 
2003 299,706 73,301 88,859 97,152 
2004 347,470 66,767 84,863 93,941 
2005 393,121 67,522 87,295 97,345 
2006 467,819 108,024 125,655 137,649 
 
Annual mortality adjusted cohort sizes increase with decreasing compliance 
rates. In Scenario 1, cohort size rises from around 38,100 persons in 1996 to 
125,700 in 2006. This corresponds to an increase of 5 % and 16 % respec-
tively compared to the basecase. In scenario 2, the first cohort comprises 
roughly 39,100 persons while the 2006 cohort consists of 137,600 persons 
representing an increase of 7 % and 27 % respectively compared to the base-
case.  
influence of compliance 
on cohort size and 
health gains 
cohort size increases 
with decreasing 
compliance by 5 % to 27 
% 
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With respect to cardiovascular health states of unstable angina, MI and 
stroke, model outcomes show that although more patients are taking statins 
overall and could therefore benefit from the treatment, the bearing on health 
gains is partly counterbalanced by lower effectiveness of the medication 
when people stop taking statins over time. The lower the compliance rates, 
the lower are the health gains (see Table 5.5-4, Table 5.5-5, Table 5.5-6).  
Yet, while the effect on unstable angina and stroke is minor, a significant 
impact is related to MI health gains (Table 5.5-5), where compliance scenar-
ios 1 and 2 result in around 200 and 300 fewer MIs avoided respectively. 
Table 5.5-4: Impact on unstable angina health gains in different compliance 
scenarios (absolute numbers) 
Diff: difference; USA: unstable angina 
 
Table 5.5-5: Impact on myocardial infarction health gains in different 
compliance scenarios (absolute numbers) 
Diff.: difference; MI: myocardial infarction 
higher number of statin 





…more health gains in 
MI… 
Year






1997 599 552 -47 533 -66
1998 688 666 -23 648 -41
1999 1132 1097 -36 1046 -86
2000 1560 1520 -41 1474 -86
2001 1805 1783 -22 1735 -71
2002 2016 2005 -11 1964 -53
2003 2509 2477 -32 2422 -87
2004 3250 3183 -67 3111 -139
2005 3681 3619 -62 3541 -140
2006 4132 4072 -61 3984 -149








1997 11 10 -1 10 -2
1998 18 16 -2 16 -2
1999 31 28 -3 26 -4
2000 45 41 -4 39 -6
2001 57 53 -4 51 -7
2002 69 65 -4 62 -7
2003 84 79 -5 76 -8
2004 106 100 -6 95 -10
2005 125 118 -7 113 -12
2006 144 136 -8 131 -13
2007 175 164 -11 157 -17
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Additionally, reduced compliance results in fewer fatal events avoided. This 
is primarily the case for CHD, where in compliance scenario 1 and 2, up to 
70 and 130 fewer CHD deaths are avoided respectively (Table 5.5-7). More-
over, the model predicts that compared to the base case, up to 30 and 60 
fewer fatal MIs respectively would occur (Table 5.5-9). Yet, with respect to 
fatal stroke with a history of CHD, the impact from different compliance 
scenarios is negligible (Table 5.5-8) 










1997 224 207 -17 198 -26
1998 246 240 -5 232 -14
1999 412 402 -10 381 -31
2000 569 558 -11 538 -31
2001 662 658 -5 636 -26
2002 778 773 -5 749 -28
2003 950 939 -10 912 -38
2004 1243 1219 -23 1182 -61
2005 1419 1398 -21 1356 -62
2006 1616 1594 -22 1546 -69
2007 2061 1991 -70 1929 -132  
Diff.: difference; CHD: coronary heart disease 
 









1997 17 16 -1 15 -2
1998 23 22 -1 21 -2
1999 38 36 -1 34 -3
2000 55 53 -2 51 -4
2001 68 66 -2 64 -4
2002 83 81 -2 78 -5
2003 104 101 -3 97 -7
2004 136 132 -4 126 -9
2005 162 157 -4 151 -11
2006 190 185 -5 177 -12
2007 239 230 -9 220 -19
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Table 5.5-8: Impact on avoided cerebrovascular deaths with history CHD in 










1997 1 1 0 1 0
1998 2 2 0 2 0
1999 3 3 0 3 0
2000 5 5 0 5 0
2001 7 7 0 6 0
2002 8 8 0 8 0
2003 11 10 0 10 -1
2004 14 13 0 13 -1
2005 17 17 0 16 -1
2006 21 20 -1 19 -2
2007 26 25 -1 23 -3  
Cerebrov. death: cerebrovascular death; Diff.: difference 
 
Table 5.5-9: Impact on reduced fatal MI in different compliance scenarios 
(absolute numbers) 
Diff.: difference; MI: myocardial infarction 
 
Furthermore, the impact of compliance scenario 1 and 2 on reduced revascu-
larisation interventions is analysed. Model outputs show that the impact is 
minor. In some years slightly more interventions are avoided in the sensitiv-
ity analysis scenarios (especially in the case of CABG) while in some years 
reduced compliance results in slightly more revascularisation interventions 
than in the base case (Table 5.5-10).  
 
 










1997 107 99 -8 94 -13
1998 118 115 -3 111 -7
1999 197 192 -5 182 -15
2000 272 267 -5 257 -16
2001 316 314 -2 303 -13
2002 371 369 -2 357 -14
2003 453 448 -5 434 -19
2004 592 581 -11 562 -30
2005 676 666 -10 645 -31
2006 769 759 -10 735 -34
2007 982 948 -33 917 -64
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Table 5.5-10: Impact on revascularisation interventions in different compliance 
scenarios (absolute numbers) 
CABG: coronary artery bypass grafting; Diff.: difference; PCI: percutaneous coronary 
intervention 
 
Finally, the applied age and gender distribution of Austrian statin patients 
is varied and the influence on the results in terms of cohort size and popula-
tion health gains is evaluated. The distribution is changed according to the 
age and gender distribution in hospital discharge data for myocardial infarc-
tion as these can be expected to be representative for persons who take stat-
ins.  
In contrast to the base case analysis, an expected value of 75 and a standard 
deviation of 14 was chosen in the gamma-distribution in the sensitivity 
analysis as this results in an age distribution which is close to the distribu-
tion of discharged patients after an MI. The ratio between males and females 
was chosen at 62:38, again representing the gender ratio of discharge data.   
As presented in Table 5.5-11, after mortality adjustment, the alternative age 
and gender distribution results in more new patients per year than in the 
base case. In 1996 there would be about 800 more patients while in 2006 the 
model predicts around 38,300 more patients. This is because discharge data 
showed a higher average age of discharged patients than assumed in the base 
case for statin takers. Thus, mortality is higher in the discharge patients. 
This affects the mortality adjusted cohort size because more statin patients 
are expected to die, thus increasing the total number of potential statin 
taker. Overall, there would be around 740,000 persons who have taken stat-
ins for secondary prevention between 1996 and 2006 in contrast to about 
600,000 in the base case. 
 
influence of varied 
gender and age 
distribution of statin 
takers: 
distribution adjusted to 
discharge data 











case scenario 1 Diff.
scenario 
2 Diff.
1997 162 149 -13 144 -18 110 101 -9 98 -12
1998 165 160 -5 157 -9 112 110 -2 107 -5
1999 260 252 -8 240 -20 177 173 -4 166 -11
2000 334 326 -8 318 -16 228 226 -3 220 -8
2001 342 341 -1 335 -8 236 238 3 234 -1
2002 350 352 2 347 -3 244 249 5 246 3
2003 387 387 1 384 -3 271 276 5 274 4
2004 495 489 -6 483 -11 346 348 1 345 -1
2005 494 493 -1 490 -4 348 354 6 353 6
2006 482 486 4 484 2 342 352 10 353 11
2007 632 606 -26 603 -30 447 437 -10 437 -9
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Table 5.5-11: Cohort size after varied gender and age distributioin 
DD: daily dose 
 
Consequently, cohort size has an effect on the outcomes in terms of popula-
tion health. Table 5.5-12 compares health gains between the statin and 
‘NoStatin’ group in the base case with health gains in sensitivity analysis.  It 
shows that the alternative gender and age distribution of statin patients re-
sults in higher health gains when the ‘NoStatin’ group is compared with the 
statin group than in the base case. The differences in terms of additional 
health gains are biggest in the case of MIs where up to 1,200 more MIs are 
avoided in the sensitivity analysis, followed by additional health gains in 
stroke prevalence and in unstable angina.  
In total, about 740,000 statin taker between 1996 and 2006 can be weighed 
against around 35,200 fewer cases of unstable angina, MI or stroke between 
1997 and 2007. This corresponds to 21 patients taking statins in order to 
achieve one fewer case of a CVD health state. The number needed to treat is 
similar to the base case. Hence, while the absolute number of CVD health 
states is lower in sensitivity analysis than in the base case, the number 
needed to treat remains unchanged because of the bigger cohort size.  
 
…more health gains 
 
biggest differences for 
MIs, yet… 
…similar number 
needed to treat 
Year
Total DD for 




























1996 13,008,421 35,640 35,640 36,257 36,257 37,060 37,060
1997 20,511,480 56,196 20,556 22,035 58,293 24,080 61,140
1998 34,051,918 93,293 37,097 39,799 98,092 43,632 104,772
1999 49,334,692 135,164 41,871 46,571 144,663 53,130 157,902
2000 61,699,193 169,039 33,875 40,166 184,829 48,817 206,719
2001 73,682,604 201,870 32,831 40,559 225,388 50,881 257,600
2002 88,031,836 241,183 39,313 49,445 274,834 62,423 320,023
2003 109,392,667 299,706 58,523 73,301 348,135 91,409 411,431
2004 126,826,414 347,470 47,764 66,767 414,901 89,630 501,061
2005 143,489,059 393,121 45,651 67,522 482,424 93,252 594,314
2006 170,753,792 467,819 74,698 108,024 590,448 146,352 740,666
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Table 5.5-12: Impact on morbidity health gains from varied gender and age 
distribution in statin patients (absolute numbers) 
MI: myocardial infarction; sensit. analy.: sensitivity analysis; USA: unstable angina 
 
Absolute results are similar for fatal events. The reduction of fatal events is 
greater when running the model with varied gender and age distribution in 
sensitivity analysis than in the base case. This is particularly the case for fa-
tal CHD (Table 5-5-13). Overall, about 740,000 statin takers between 1996 
and 2006 can be weighed against around 17,500 fewer fatal CVD events be-
tween 1997 and 2007, corresponding to a number needed to treat of 42 to 
avoid one fatal event. This is lower than in the base case suggesting that the 
increase in mortality health gains is disproportionately higher than the in-
crease in cohort size.  
Table 5.5-13: Impact on mortality health gains from varied gender and age 
distribution in statin patients (absolute numbers) 
cerebrov. death: cerebrovascular death; CHD: coronary heart disease; MI: myocardial 
infarction; sensit. analy.: sensitivity analysis 
 
On the contrary, in the case of revascularisation interventions, the results 
are almost the same when comparing base case and sensitivity analysis.  
Slightly fewer interventions are reduced in the sensitivity analysis compared 
to the base case (Table 5.5-14).  
fewer fatal events and 
lower number to treat 
in sensivitivty analysis 
low influence on 
revascularisation 
Year
 USA base 
case
 USA sensit. 
anal. Difference  MI base case






1997 11 16 -5 599 613 -14 17 36 -18
1998 18 25 -7 688 771 -83 23 46 -23
1999 31 42 -11 1132 1268 -136 38 77 -40
2000 45 61 -16 1560 1786 -225 55 111 -57
2001 57 77 -20 1805 2121 -316 68 137 -69
2002 69 93 -24 2016 2393 -377 83 166 -83
2003 84 112 -28 2509 2973 -464 104 205 -101
2004 106 142 -37 3250 3853 -603 136 267 -131
2005 125 169 -44 3681 4471 -790 162 316 -155
2006 144 195 -52 4132 5078 -946 190 368 -178
















1997 224 397 -173 1 3 -2 107 191 -84
1998 246 420 -174 2 8 -5 118 202 -84
1999 412 716 -303 3 11 -8 197 343 -146
2000 569 986 -416 5 17 -12 272 472 -200
2001 662 1136 -474 7 23 -16 316 544 -227
2002 778 1322 -544 8 27 -19 371 632 -261
2003 950 1611 -661 11 33 -23 453 770 -317
2004 1243 2129 -887 14 43 -29 592 1018 -426
2005 1419 2432 -1013 17 53 -35 676 1162 -486
2006 1616 2761 -1145 21 62 -41 769 1318 -549
2007 2061 3618 -1557 26 76 -50 982 1728 -747
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Table 5.5-14: Impact on revascularisation interventions from varied gender and 
age distribution in statin patients (absolute numbers) 
CABG: coronary artery bypass grafting; PCI: percutaneous coronary intervention; 











1997 162 153 9 110 103 7
1998 165 164 2 112 110 2
1999 260 252 8 177 172 5
2000 334 324 9 228 223 5
2001 342 330 12 236 231 5
2002 350 329 22 244 234 10
2003 387 354 33 271 256 15
2004 495 457 38 346 329 18
2005 494 461 32 348 335 12
2006 482 442 39 342 327 15
2007 632 607 25 447 443 4
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6 Discussion 
In this analysis we have addressed two major issues with respect to statin 
treatment in Austria. First, we analysed the expected population health 
gains from statin treatment between 1996 and 2006 in Austria in terms of 
different types of cardiovascular diseases and revascularisation interven-
tions. Second, incremental cost-utility ratios for statin treatment compared 
to non-statin treatment for a life-time perspective and for a 10-year time ho-
rizon were evaluated.  
According to the base case results, overall around 600,000 persons took stat-
ins between 1996 and 2006 in Austria. This amount included those who had 
died within that time period.  
With respect to population health gains in cardiovascular morbidity, base 
case model outputs showed that the biggest health gains could be expected 
with respect to MI. Between 600 and 5,000 MIs per year and 26,600 MIs in 
total were avoided or postponed in estimates comparing the statin group to 
the ‘NoStatin’ group in Austria. On the other hand, the model has shown 
that the prevalence of stable angina has risen in the statin group. This is 
probably due to the fact that the use of statins results in people staying 
longer in the less severe health state of stable angina. In terms of stroke, 
predicted health gains are considerably smaller. However, this is because 
only strokes with a history of CHD have been considered in the analysis. 
Moreover, efficacy data from clinical studies which are the basis for the 
model have shown that statins have a lower impact on stroke than on CHD.  
Estimated health gains in terms of avoided/postponed fatal events are larg-
est with respect to fatal CHD. In the base case, the proposed number of 
avoided or postponed CHD deaths between the statin and the ‘NoStatin’ 
group rose from 224 in 1997 to 2,061 in 2007 resulting in a total number of 
around 10,200 avoided/postponed fatal events for the whole period evalu-
ated. Fatal MIs account for the biggest proportion of fatal CHDs avoided. 
The health gains in terms of reduced fatal cerebrovascular diseases for those 
with a history of CHD, however, are almost negligible. This is mainly due to 
the fact that statins have not shown a significant effect in the meta-analysis 
in terms of fatal cerebrovascular disease.  
In terms of revascularisation, it was estimated that around 7,000 interven-
tions were avoided in a total number of 600,000 persons who took statins 
compared to not taking statins.  
For all outcome parameters evaluated, health gains are lower for women 
than for men. This is consistent with the model parameters where, firstly, it 
has been assumed that slightly more men than women are taking statins 
and, second, that – based on epidemiological data – a higher proportion of 
men than of women undergo more severe health states.   
Apart from health gains, however, the model additionally demonstrated that 
in the 600,000 patients who took statins between 1996 and 2007, 4,400 cases 
of USA, 35,200 cases of MI and 2,300 cases of stroke were occurring. Fur-
thermore, it was estimated that 24,000 fatal CHDs and 1,400 fatal cere-
brovascular events occurred despite statin treatment. Finally, 231,000 revas-
cularisation interventions were carried out in spite of statin treatment.  
two  issues analysed:  
population health gains 
+ cost-utility ratios 
1996-2006:              
600,000 persons have 
taken statins 
 
26,600 MI avoided, 
increasing prevalence of 
SA,  
 
impact on stroke is 




events, most of them MI 
 






more health gains for 
men –  
less women taking 
statins 
despite statins cases of 
CVD occur 
Statins for the Secondary Prevention of Cardiovascular Diseases 
64 LBI-HTA | 2008 
Thus, despite statin treatment, a considerable number of patients were in 
one of the health states evaluated, experienced a fatal CVD event or needed 
to undergo revascularisation. Overall, around 45,000 ‘avoided health states’, 
events or interventions need to be measured up against around 300,000 cases 
in CVD morbidity health states (excluding stable angina), fatal events or in-
terventions that still have occurred. Moreover, (fatal) events that can be 
avoided in one year may simply occur later on, thus postponing rather than 
truly avoiding the events. 
The number of persons that needed to be treated to achieve one fewer case of 
a CVD morbidity health state was 21. For avoiding one fatal event, 59 per-
sons needed to be treated. For every revascularisation intervention avoided, 
86 persons needed to take statins. These figures are consistent with the re-
sults from clinical studies which showed a number needed to treat of 34 
(22.8-95.5) in the 4S-Study and of 12 (9-16.4) in the CARE study for the 
combined endpoint of CHD mortality and morbidity [14]. 
Concerning life-time effectiveness, the model predicts average undiscounted 
incremental QALYs per person of 1.13 and 1.32 (13.6 and 15.8 quality ad-
justed life months) for the youngest age groups (45 years) of males and fe-
males respectively. QALYs decrease with age to 0.27 and 0.31 (3.2 and 3.7 
quality adjusted life months) for males and females aged 85 respectively.   
Population net costs are higher in the treated cohort compared to the 
‘NoStatin’ group. In the former, they ranged from 33 million Euros in 1996 
to almost 700 million Euros in 2007. It has been estimated that potential cost 
savings ranged from 8 million Euros in 1997 to 105 million Euros in 2007. 
However, these results could not be derived from the model directly and are 
therefore subject to some uncertainty.  
Base case incremental cost-utility-ratios are below 30,000 Euros per QALY 
gained in all age groups and in both, males and females. ICURs decrease 
with age which means that treating people in higher ages decreases the addi-
tional resources required to gain an extra QALY. With respect to gender, in 
younger age groups results are slightly more favourable in females than in 
males. This difference reverses at the age of 75 above which results are more 
favourable for males.  
Results from the various one-way sensitivity analyses show that ICURs may 
be lower than in the base case (when lower discount rates and statin prices 
are assumed) but do not exceed 35,000 Euros per QALY even when factors 
with the opposite impact are varied (e.g. compliance). The results can there-
fore be considered as conservative as well as robust with respect to a theo-
retical willingness-to-pay-limit of 35,000 Euros per QALY. Yet, the analysis 
for a 10-year time frame has shown a different picture. Cost-utility ad-
dressed from a short time perspective results in considerably higher ICURs 
(above 50,000 Euros per QALY gained) in the younger age groups. Hence, 
overall cost-utility ratios can be considered as robust only when a lifetime 
approach including long-term treatment is guaranteed. 
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Cost-effectiveness results are consistent with those from the original model 
as well as with other international studies.  Yet, when comparing age specific 
results, ratios are higher in younger age groups and lower in older age 
groups in the Austrian case than in the original UK model. This may be ex-
plained by differences in overall life-expectancy between the two countries. 
However, since ratios in all age groups are within a similar range for each 
country, the country-specific differences are considered to be of little conse-
quence. Nonetheless, interpretation of cost-utility ratios is limited in Aus-
tria, since no threshold exists for what is to be considered a favourable cost-
utility ratio in the Austrian health care system. One useful indicator may be 
that derived from international studies on statins in which – based on a 
utilitarian approach – results below 30,000 Euros per QALY have generally 
been considered favourable [2]. 
The study has several limitations:  
First, the results on population health gains as well as the cost-utility ratios 
are based on the ScHARR Markov model which uses primarily UK data for 
populating the model. Wherever available, British data have been replaced 
with Austrian ones which is the case for life-expectancy data, data on health 
state costs and statin cost data. Yet, many other data were not available for 
Austria, such as utility data for the various health states included in the 
model, information on the initial distribution of patients into different 
health states and transitional probabilities for patients moving from one 
health state to another in the untreated cohort (including baseline risks). 
These issues –in particularly the lack of information on baseline risks [43] – 
are clearly a limitation of the model. However, sensitivity analysis in the UK 
study has shown that neither of these parameters had a major influence on 
the final results of their study. Thus, as it has been suggested in a methodo-
logical study on transferability [44], it can be assumed that uncertainty with 
respect to these limitations is low in the adapted Austrian model with re-
spect to cost-utility results.  
On the contrary, sensitivity analysis for the population health gain model 
has shown that results are subject to considerable uncertainty. This is espe-
cially the case when the age and gender distribution of statin takers is var-
ied. The variation applied does not only result in larger cohort sizes than in 
the base case, but subsequently influences population health gains which are 
also greater in sensitivity analysis than in the base case, indicating again a 
conservative approach. Varying compliance has some affect on the cohort 
size, too. Yet, health gains remain fairly stable as the potential health gains 
from more people taking statins is compensated by lower statin efficacy 
when it is assumed that these people are less compliant.  
Not least, estimated cohort size and subsequent impacts on population 
health are very much dependent on the prescription data available. If statins 
prescribed were in fact less restricted to secondary prevention than the regu-
lation in chapter 3.4.1 suggests, the cohort size (and the health impact) may 
be overestimated. Since the regulation for prescription was changed in 2004 
to a more risk-related approach, there will certainly have been be a number 
of prescriptions for patients who did not fall within our definition of secon-
dary prevention from 2004 to 2006. This again suggests  a possible overesti-
mation of population health gains. 
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Another limitation is related to the health state cost data used in the model. 
Data are based on administrative prices and not on precise cost calculation 
which is suboptimal. Yet, no other data have been available and, moreover, 
variation of health state costs has not had a significant influence on the re-
sults in sensitivity analysis. Furthermore, the costs for statin treatment are 
based on a weighted average of expenditure for different types of statins be-
tween 1996 and 2006. This seems appropriate for the population cost analy-
sis which is done for the same time period. However, with respect to the life-
time cost-utility analysis, ICURs may be overestimated as costs per prescrip-
tion have decreased over time and may remain at a low level in the long run. 
As sensitivity analysis has shown, lower statin costs have resulted in lower 
(better) ICURs.  
In relation to costs, it is also a limitation of the study that health care sector 
costs only have been included, thus we cannot depict the total societal con-
sequences (e.g. informal care, productivity etc.) from statin therapy. 
Furthermore, results are based on data from clinical studies which may dif-
fer in routine clinical practice. This is most important for compliance and 
the reduced effectiveness of statin therapy this relates to. Overall, the evi-
dence available on compliance rates has been poor in quality. However, as 
the UK model illustrates, reduced compliance combined with failure to re-
trieve a prescription does not incur costs either and thus does not greatly in-
fluence the cost-effectiveness results. Only in the case of patients who fail to 
take medication but pick up prescriptions, cost-utility results are less fa-
vourable. On the contrary, as previously mentioned, compliance that is poor 
has been shown to have an impact on the cohort size in the population 
model but less on the estimated population health gains.  
In terms of statin efficacy, differentiating the various statins on the basis of 
the evidence from the placebo-controlled trials used in the model was not 
possible. Hence, the combined evidence for each outcome was used in the 
model thus making a comparison of the results between different statins im-
possible as well.  
Generally, a long extrapolation of clinical study results is required for cost-
utility analyses over a life-time. This increases uncertainty - particularly in 
the younger age groups in which the data used for populating the model (e.g. 
distribution into different health states) are generally of lower quality than 
the data from older age groups [14].  
Finally, some further limitations indicate future research requirements. As 
outlined in the beginning of this report, our study was restricted to secon-
dary prevention only. Because statins were more or less confined to secon-
dary prevention in the period addressed in order to calculate population 
health gains, the focus chosen seems appropriate in that case. For the cost-
utility analysis, it would be equally interesting to address primary preven-
tion as well, especially since indications were extended in 2004 to include 
additional patients at risk of CVD.  
Furthermore, in terms of sub-groups, the study was limited to age and gen-
der specific outcomes but did not address disease-specific sub-groups such 
as people with diabetes. In the latter case, economic evaluations (especially 
in primary prevention) have usually shown more favourable results than 
when addressing the total population at risk [17]. Moreover, the study did 
not consider socio-economic variations in the uptake of or access to statins 
which may be another sub-group analysis of interest.  
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7 Conclusion 
In summary, results suggest that prescribing statins to about 600,000 to 
750,000 patients from 1996 to 2006 should have resulted in observable health 
gains compared to the alternative of not taking statins. This is especially the 
case for avoided non fatal MIs and reduced CHD mortality, while the im-
pact on stroke (for those with a history of CHD), cerebrovascular mortality 
and revascularisation interventions is significantly smaller.  
However, the study also demonstrated that despite statin treatment, a con-
siderable number of patients still were in one of the health states evaluated, 
experienced a fatal event or needed to undergo revascularisation. Overall, 
around 45,000 ‘avoided CVD health states’, events or interventions need to 
be weighed against around 300,000 cases of CVD health states, fatal events 
or interventions that still occurred. The results are based on the effect size 
that statins have shown in clinical studies. 
Additionally, potential cost savings exist, yet they are small in comparison to 
the total costs involved. Nevertheless, cost-effectiveness ratios from statin 
therapy in comparison to non-medical treatment are below 35,000 Euros per 
QALY and can be considered as robust when a lifetime perspective is con-
sidered. Although interpretation of cost-utility results is limited in Austria, 
results below 35,000 Euros per QALY have been rated as cost-effective in 
most international studies.  However, viewed from a short term perspective 
of ten years, cost-utility ratios are considerably higher than 35,000 Euros per 
QALY for most age groups. 
While cost-utility results have been shown to be robust (except for a 10-year 
time horizon), estimated population health gains are quite sensitive to the 
assumed variations in the gender and age distribution of statin taker in Aus-
tria. Health gains in base case results are lower than in sensitivity analysis 
results and can therefore be considered conservative. Consequently, the di-
mension of health gains is subject to considerable uncertainty and a precise 
number of events avoided cannot be calculated with the approach chosen. 
Additionally, the cohort size of Austrian statin takers also varies considera-
bly in the sensitivity analyses applied, thus the ‘true’ size and characteristics 
of Austrian statin taker is also subject to some uncertainty. More detailed 
primary and patient-level data on statin prescription would help to over-
come this limitation.  
Overall, whether the expected health gains are sufficient when considering 
the number of CVD events still occurring as well as the costs is a matter of 
political debate.  
Finally, the results are based on the outcomes of clinical studies on statins 
and whether the estimated ‘theoretical’ health gains from statins in this 
study correspond with observed cardiovascular epidemiology and real-life 
population health in Austria remains to be seen. This issue is addressed in a 
subsequent project which will be presented in a separate report [42].  
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9 Appendix 









9. co reductase inhibitor*[tw] 
10. lipid lowering[tw] 
11. OR/1-10 
12. coronary disease/ 
13. (coronary OR heart OR arter*)[tw] 





Statins for the Secondary Prevention of Cardiovascular Diseases 






Search resulted in 905 hits (mostly: surrogate endpoints, combinations with 
ezetimib, treatment with statins for acute MI, aggressive cholesterol lower-
ing, treatment to new targets) 
34 were selected at abstract stage  
Inclusion criteria: RCT or meta-analysis of RCT, outcome parameter clini-
cally relevant (non-fatal CVD event, fatal CVD event, hospital intervention, 
adverse events, specific subgroupanalysis – especially gender and diabetes, 
adverse events, German and English language) 
Exclusion criteria: other language, non-western countries (Asia), surrogate 
endpoints, economic evaluation 
 
Full paper: 
n = 34 
 
Excluded references: 
n = 871 
 
Included full papers: 
n = 21 
 
Excluded full papers: 
 
n = 13 
 
• 7 surrogate endpoints, wrong 
study design 
• 6 primary prevention 
Full paper not available: 
n = 0 
Abstract only: 
n = 0 
   
Background li-
terature: 
n = 0 
Identified references:  
n  = 905 
Appendix 
LBI-HTA | 2008 75 
Table 9-1: Included studies in literature update 
N =21 Characteristics 
6 Adverse effects 
1 Gender specific meta analysis 





General Trials or Meta- Analysis 
- Atorvastatin 
- Fluvastatin 
- Meta Analysis 
3  Stroke Outcome 
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Table 9-2: Service patterns and unit costs 
 
Health states/services Type of services used Frequencies Unit costs Sources comments 








Year 1:  
2 specialist (internal medi-
cine) visits + ECG + Ergo 
+ Echo) 
Medication: Nitrat, ACE 
inhibitor, beta-blocker, as-
pirin (partly) 
Monitoring: 4 times a 
year; HDL, LDL, Total 
cholesterol, Triglycerid,  
 
 
Subsequent years: as year 
1 
Internal medicine: € 18.02 
ECG: € 21.26 
Ergometry: € 68.35 
Echocardiography: € 49.58 
 
Nitrate: € 11.37 
ACE inhibitor: € 15.80 
Beta-Blocker: € 11.73 
Aspirin: € 0.05 
 
HDL, LDL: € 4.86 
Total Cholesterol: € 4.68 
Triglycerids: € 5.57 
 
Federation of the Aus-




Aspirin is only calcu-
lated for a part of the 
patients as it will 
mostly be paid out of 
pocket. 
Unstable Angina See stable angina See stable angina See stable angina   
Non-fatal MI Hospital care 
 




Year 1:  
1x hospital admission + 
Primary care services (see 
stable angina) 
 
Subsequent years: primary 
care services (see stable 
angina) 
 
Hospital treatment: € 4,835 
 
Primary care: see stable angina  
LKF-data; 
Federation of the Aus-





Fatal MI Hospital care 1 x hospital admission Hospital treatment: € 4,835 LKF-data;  
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DD: daily dose; LKF: Leistungsorientierte Krankenanstaltenfinanzieru 
 
 
Non-fatal Stroke Hospital care; 
Primary care services: 
Specialist consultant (In-





Year 1: hospital care 
Primary care services (see 
stable angina) 
+ 2 times a year neurolo-
gist 
+ 4x3x10 physiotherapy 
sessions 
 
Subsequent years: as year 
1 but without hospital care 
and physiotherapy 
 
Hospital treatment: € 3,897 
 
 
Neurologist: € 18.02 
 
Physiotherapy: € 1,301.35 
LKF-data; 







Fatal Stroke Hospital care 1 hospital admission Hospital treatment: € 3,897 LKF-data  
Statin therapy Medication 
Monitoring 
DD of Statins 
 
1 GP visit per prescription 
Monitoring: GOT, GPT, 
Gamma-GT, Creatinin, 
CK, CK-MB 
Statins per DD: € 0.93  (= € 340.96 per 
year (weighted average) 
GP: € 12.39 
 
GP: € 12.39 
GOT: € 6.12 
GPT: € 5.98 
Gamma-GT: € 6.17 
Creatinin: € 4.35 
Creatininkinase: € 4.67 
CK-MB: € 7.21 
  
